annual report access healthcare important lifechanging innovation meaningful reach need access core business consider key commitment improve patient outcome combine strength diagnostic pharmaceutical position play decisive role patient journey partner stakeholder address root cause global country community level prevent access innovative healthcare matter people live rochecomaccesscontent shareholder letter business performance report strategy diagnostic pharmaceutical personalise healthcare access healthcare people culture environment community engagement business ethic corporate governance remuneration report rochecomreportingletter shareholder year roche work improve health countless people world trust shareholder guide scientific progress continue identify seize opportunity futuredr christoph franz chairman basel switzerland final letter shareholder christoph franz reflect company performance countless collaboration partner world increase access healthcare everyoneletter shareholder roche dr severin schwan ceo roche group basel switzerland time ceo severin schwan share thought progress patient society advance digital healthcare dr christoph franzchairmans shareholder letter roche dear shareholder company achieve good result world improve access medicine year challenge environment sale diagnostic improve people live increase net income amount billion swiss franc board director example partnership project propose annual general meeting echo nonprofit organisation use video dividend increase swiss telementore medical education care franc share nonvoting equity security management project connect national th increase succession centre excellence remote underserved area give patient access specialised care challenge past year not receive manifold particular war ukraine bring unimaginable suffer millions good healthcare lifesave patient people massive impact create enormous value society economy time people imagine mean person cancer world preoccupy consequence cure thank timely accurate diagnosis covid pandemic effective treatment continue family contribute connection war ukraine able society economy early diagnosis experience particularly impressive way prevent illness altogether avoid costly employee fully commit provide patient hospital stay medicine diagnostic test deeply grateful incredible helpfulness initiative hope access modern effective employee border healthcare day possible world roche make significant currently roche total number new contribution compound additional indication clinical development registration diagnostic final letter esteemed shareholder division flourish thank continuous roche year board development new innovative instrument director include chairman test confident decide stand reelection future roche general meeting severin schwan designate new chairman board innovation reach people need director thomas schinecker new ceo work healthcare partner roche lead future strong country roche engage hundred highly experienced team partnership collaboration state growth rate comparison previous year constant exchange rate cer average rate total figure quote report chf severin schwan thomas schinecker roche lead future strong highly experienced team like thank severin schwan great honour work sincerely outstanding achievement unique excellent company roche success ceo roche year particular fact company trust respectful cooperation own founder descendant severin schwan contribute decisively year owner family longterm orientation major success company particularly enable leadership roche right like highlight integration genentech decision company continue milestone development roche equally major contribution people health noteworthy fact pharmaceutical year ahead thank owner business compensate loss family great support patent protection topselle medicine thank introduction new innovative like particular thank roche product recent year employee significant medical advance achieve thank finally delight able dear shareholder trust strengthen board director roche key personality board director propose mark schneider ceo nestl akiko iwasaki professor immunobiology molecular cellular developmental biology yale university researcher howard hughes medical institute annual general meeting election dr christoph franz new board member chairmanchairman shareholder letter roche roche board director december bernard poussot c e g dr jrg duschmal representative shareholder group pool voting right b e g dr christoph franz chairman c e g andr hoffmann vicechairman representative shareholder group pool voting right c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g dr patrick frost b c e g anita hauser e g prof dr richard p lifton c e g dr jemilah mahmood e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson thank christoph franz years general meeting christoph franzs give people worldwide access medicine year work head company diagnostic come end year board christoph franzs particular concern director year chairman christoph travel roche subsidiary africa asia franz decide stand reelection south america take time visit local hospital talk doctor doubt tenure local nursing staff patient outgoing chairman strongly influence roche local government representative effect strategic development considerable remarkable number agreement personal contribution success roche government world company join roche aim work improve local christoph franz able valuable healthcare system contribution board director outset undoubtedly result personally appreciate year experience international company christoph franz wealth entrepreneurial board director experience widerange knowledge executive committee simply manage advocate obvious solution problem tackle promptly provide particular challenging choice constructive solution confidently key safeguarding successfully steer company roche future challenging time great dedication example like mention include roche behalf entire board director contribution pandemic handle oeri hoffmann duschmal family patent expiry widely like sincerely thank chairman cancer medicine addition christoph franz important contribution expand roche strategic flexibility repurchase roche share hold novartis take role roche digitalisation healthcare sector accelerate alongside farreache transformation company roche today andr hoffmann clearly different roche decade ago vicechairman board directorsletter vicechairman roche andr hoffmann dr severin schwanshareholder letter ceo roche group roche dear shareholder overall achieve good result year highlight cancer immunotherapy primarily continue strong demand tecentriq approve europe routine diagnostic new medicine country treatment early treat disease multiple sclerosis stage lung cancer people raise haemophilia severe eye disease spinal muscular prospect cure atrophy cancer innovative research development development delivery pioneer carry opportunity risk addition medicine diagnostic heart success experience setback mission innovation roche improve life year foremost disappointing people worldwide billion test study datum gantenerumab treatment perform diagnostic product deliver alzheimer disease setback crucial information disease prevention diagnosis reason long treatment million patient treat iterative research development process roche medicine industry learn study datum implement lesson study particularly please recent success roche molecule alzheimer ophthalmology vabysmo novel treatment development continue certain severe eye disease launch entrepreneurial courage invest particularly begin large number patient highrisk research area alzheimer access innovative eye medicine hope ultimately achieve breakthrough vabysmo important growth patient driver month innovative diagnostic solution enable early year able provide patient reliable decisionmake infectious important medicine blood cancer disease cancer disease pcr lunsumio give hope people certain form test kit develop record time detection follicular lymphoma blood cancer develop mpox virus prove slowly incurable new covid able respond quickly immunotherapy activate bodys immune new public health threat system promise new approach blood cancer polivy significantly improve chance cure certain human papillomaviruse hpv particularly aggressive form blood cancer cause cervical cancer new hpv selfsample decade research area little solution offer woman possibility progress real medical breakthrough cervical sample need hpv testing roche corporate executive committee december dr alan hippe chief financial information officer claudia bckstiegel general counsel dr aviv regev head genentech research early development gre prof dr hans clever head roche pharma research early development pre dr severin schwan ceo roche group cristina wilbur chief people officer bill anderson ceo roche pharmaceutical barbara schdler head group communications dr james h sabry global head pharma partner dr thomas schinecker ceo roche diagnostic member enlarge corporate executive committeeshareholder letter ceo roche group roche particularly please bring new medicine patient vabysmo certain severe eye disease lunsumio currently incurable form blood cancer healthcare facility diagnostic digital solution roof solution help break barrier screen roche position perform pioneer cervical cancer new hcv duo assay work field time help prevent cancer disease year history cause hepatitis c assay provide antigen antibody result test like thank employee help diagnose hepatitis c fast tireless commitment challenging year expand digital like thank chairman christoph health business example new digital franz year confidenceinspire solution pathology deliver highresolution work passionate ensure digital image tissue sample fast product solution reach people evaluation carry microscope desperately need matter live electronically artificial intelligence see human eye make easy thomas schinecker role ceo diagnose cancer enable target midmarch like thank effective treatment patient concerned outstanding work head diagnostic division look forward continue work fragmented healthcare system medical knowledge untappe today inadequate digitalisation s thank dear shareholder trust cloudbase platform cobas infinity edge come company play enable nursing staff doctor securely share patient datum multiple source bring range health datum electronic patient record thirdparty app pointofcare service digital transformation bring huge dr severin schwan advance patient pharmaceutical ceo roche groupbusiness performance roche business performance achieve good result expect demand covid product decline diagnostic base business new medicine continue strong growth un sdgs material topic longterm mindset key figure chf million group sale pharmaceutical sale diagnostic sale core operating profit rd core investment chf dividend state growth rate comparison previous year constant exchange rate cer average rate total figure quote report chfbusiness performance roche diagnostic pharmaceutical employee operate divisional group corporate chugai research development site pharmaceutical manufacturing site pharmaceutical diagnostic worldwide diagnostic worldwide million patient roche medicine treat roche medicine model list essential medicine number employee express fulltime equivalent roche group roche sale rise chf expect impact biosimilar chf billion core operating profit increase sale cancer medicine mabtherarituxan chf reflect good underlie herceptin avastin continue slow business performance result combine chf billion reduction sale ifrs net income chf billion decrease compare high diagnostic division increase sale impairment intangible asset high interest chf billion division base business cost income taxis achieve good result year region growth mainly drive core earning share grow chf immunodiagnostic product include positive impact repurchase roche share hold novartis broad portfolio covid test generate sale totalling chf billion compare pharmaceutical division sale increase chf billion chf billion new medicine treat severe disease continue strong growth vabysmo outlook eye medicine launch begin sharp decline sale covid growth driver product roughly chf billion roche expect medicine ocrevus multiple sclerosis decrease group sale low single digit hemlibra haemophilia evrysdi spinal muscular range constant exchange rate exclude atrophy tecentriq cancer generate covid sale decline roche anticipate solid additional sale totalling chf billion underlying sale growth division sale covid medicine generally core earning share target develop low decline roughly chf billion broadly line sale decline constant decrease sale actemraroactemra exchange rate roche expect increase severe covid pneumonia partially dividend swiss franc sale growth ronapreve highrisk patient japan state growth rate comparison previous year constant exchange rate cer average rate total figure quote report chf ifrs result include noncore item global restructuring plan amortisation impairment goodwill intangible assetsbusiness performance roche roche group pharmaceutical division sale chf million diagnostic division diagnostic diagnostic division sale grow emergency room medical practice directly chf billion division base business patient include sarscov rapid test achieve good result year blood gas electrolyte test region growth mainly drive immunodiagnostic product molecular lab sale decrease lower covidrelate sale north america broad portfolio covid test generate emea region partly offset sale totalling chf billion compare growth base business portfolio chf billion customer area focus molecular lab sale asiapacific north america region provide diagnostic solution pathogen increase respectively detection monitor donor screen sexual drop sale europe middle east africa health genomics emea region primarily reduced demand covid testing diabete care sale decrease base effect resolution rebate dispute core lab sale increase immunoassay exclude effect sale remain stable cardiac oncology test clinical continue contraction blood glucose chemistry product main growth driver monitor market particular united states sale grow region strongly europe offset high demand asiapacific emea latin america emerge market customer area focus central lab customer area focus integrate provide diagnostic solution personalise diabetes management people area immunoassay clinical chemistry diabete healthcare professional custom biotech pathology lab sale increase point care sale grow sarscov growth advance stain rapid antigen test continue main companion diagnostic business sale growth driver demand cobas sarscov grow region influenza ab assays increase large contribution come asiapacific customer area focus pathology labs north america region provide diagnostic solution tissue biopsy companion diagnostic customer area provide diagnostic solution target diagnostic support specific immediately point care therapy decision patientbusiness performance roche sale customer area chf million core lab point care molecular lab diabetes care pathology lab pharmaceutical pharmaceutical division sale increase indication remain strong united chf billion new medicine treat severe states europe international region disease continue strong growth medicine continue high uptake sale united states decrease slightly perjeta chf billion herpositive sale growth new medicine breast cancer sale increase ocrevus vabysmo hemlibra tecentriq partially continue high demand international region compensate sale decline actemra mainly china roactemra covid medicine patent expire hemlibra chf billion haemophilia factor viii inhibitor europe sale slightly prophylactic treatment administer mainly low sale covid medicine subcutaneously weekly ronapreve exclude base effect sale week sale continue impressive europe increase new medicine uptake especially united states europe offset impact biosimilar sale international region grow major market sale japan increase substantial key factor supply ronapreve tecentriq chf billion cancer government follow sale growth evrysdi immunotherapy combination polivy hemlibra enspryng type cancer eg lung bladder offset impact biosimilar government breast liver cancer sale increase price cut high demand united states europe sales japan decrease primarily sale international region grow governmental price cut china sale decrease biosimilar low sale rocephin local covid actemraroactemra chf billion measure exclude china sale region rheumatoid arthritis form juvenile idiopathic increase mainly result high arthritis giant cell arteritis car tcellinduce demand perjeta hemlibra ocrevus kadcyla severe lifethreatening cytokine release syndrome covid sale decrease mainly ocrevus chf billion relapse united states international region primary progressive form multiple sclerosis drive low demand patient severe twohouronly infusion demand ocrevus covid pneumoniabusiness performance roche topselling pharmaceutical chf million ocrevus neuroscience perjeta oncology hemlibra haemophilia tecentriq oncology actemraroactemra immunology xolair immunology herceptin oncology avastin oncology kadcyla oncology mabtherarituxan oncologyimmunologyreporte strategy roche reporting strategy roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance sustainability build business strategy everyone job roche focus find new medicine diagnostic establish database insight evolve practice medicine help patient live long well life report approach roche commit transparent reporting review externally appropriate endeavour drive economic social risk management embed level environmental performance diligence roche group pharmaceutical diagnostic financial performance division global function conduct formal risk opportunity assessment report scope boundary year develop response plan financial nonfinancial reporting consist material risk opportunity annual report finance report online report contain annual financial read corporate governance statement consolidated financial statement nonfinancial performance indicator cover identify longterm business sustainability region division roche group trend associate risk opportunity january december financial annual basis integrate exist reporting scope define outlined group risk management process year finance report significant emerge trend include associate risk change scope compare opportunity identify internal external source gri standard materiality member global reporting base finding sustainability steering initiative gri community committee prioritise select business follow gri g guideline sustainability trend important transitioned reporting reference business sustainability trend gri standard gri standard follow future work ii mistrust disclose critical impact activity scepticism science trend environment society economy associate opportunity risk describe risk management risk management policy set roche un sustainable development goal approach identify analyse manage support united nations sustainable report internal external risk development goal sdgs sphere opportunity consolidate group risk report corporate business strategy contribute cover material risk opportunitie number sdgs great contribution discuss annually corporate executive sdg good health wellbeing goal committee review board director closely connect achievement universal health coverage go hand hand effectiveness group risk management well access quality essential medicine process regularly monitor group risk diagnostic fully align vision advisory team overall process review improve save life sdgs audit committee board director integral annual reporting report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicator rochecomperformanceour reporting approach roche business sustainability trend example contribution un goal list un sdg webpage link future work map material topic trend descriptor new diverse complex working model remote feature signatory un hybrid lead increasingly fluid workspace workforce global compact ungc commit integrate require agile workforce management avoid negative impact universal principle area human leverage positive impact talent attraction retention right labour environment anticorruption engagement especially highly innovationdependent sector business strategy culture daily operation report result achieve opportunity roche position attractive employer year publish communication flexible way work progress cop quarter submit second cop quarter risk disconnection company increase silo thinking reduce innovation drive duplication external assurance select key figure nonfinancial mistrust scepticism science reporting year end december trend descriptor grow educational gap populism subject limited assurance procedure increase spread fake news intend unintended lead perform pricewaterhousecoopers ag pwc mistrust scepticism science medical therapy pharmaceutical independent thirdparty assurance provider industry institution pwc provide limited assurance select key figure area safety security health opportunity competitive advantage create roche environmental protection ii people culture strengthen relationship government patient iii grant donation sponsorship key organisation payer doctor eg share information provide figure disclose annual report andor education nonfinancial reporting webpage relate pwc limited assurance report risk patient society benefit scientific define nonfinancial report metric advancement result medicine lack awareness guideline basis preparation saturation false information independent assurance report list business sustainability trend associate risk opportunity find risk management website link previous materiality impact purpose patient need environment identify meet need respect healthy planet day sustainable succeed environment priority sustainability build business found family company strategy everyone job roche commit halve environmental impact operation product approach holistic integrate aim reduce greenhouse dimension sustainability gas emission absolute zero society contribute well partnering supplier reduce tomorrow emission mutual benefit environment minimise impact nature economy economy invest medical advance business meet need patient create job ensure livelihood continue create quality job provide people family secure livelihood mean roche earn competitive return investor day promote innovation translate science pioneer medicine society diagnostic help patient live long contribute well society enable well productive life enable right treatment right patient right support contribute time right value develop local economy new medicine way diagnose disease gain insight datum commitment describe strategy setup expand access innovation help design innovation autonomous research patient live long well life come development centre alliance deep respect human right external partner foster diversity reach especially patient business partner scientific approach agility roche supplier local community course operate country local colleague world emphasise team implement strategy measure employee safety health development performance report stakeholder promote diversity inclusion integrity mutual progress goal set respect equal opportunity sustainability rochecomsustainability materiality rochecommateriality stakeholder engagement rochecomstakeholderengagement key performance indicator rochecomperformance contribution un sdgs rochecomunsdgsmateriality impact roche society environment sustainability economy material topic access healthcare ethic compliance affordability healthcare compliance availability healthcare ethic transparency sustainable healthcare system human right digitalisation employee engagement cybersecurity organisational agility datum privacy preparedness age society personalise healthcare talent attraction retention realworld datum energy efficiency science innovation energy efficiency patient centricity preparedness age society longterm mindset rd efficiency longterm mindset product quality safety product safety product quality materiality assessment impactdriven sustainability initiative stakeholder engagement order maximise impact engage stakeholder essential build healthcare industry join trust understand expectation notable sustainability initiative embed feedback strategy sustainable market initiative value daily business able jointly address balance alliance common issue develop longterm solution sustainable market initiative smi order identify topic particularly multistakeholder initiative aim lead relevant roche stakeholder society transition sustainable future convene large deliver last share value public privatesector leader align conduct indepth materiality assessment economic value social environmental corporate level key stakeholder sustainability smi commitment approach materiality climate action line science assessment integrate building group base target initiative sbti value risk management process inclusive balancing alliance vba initiative design collaboratively colleague alliance multinational corporation multiple function gather insight develop pilot alongside lead academic broad range internal external stakeholder institution standardise methodology identify important press issue ensure great sustainability transparency roche address year great disclosure identify material topic cluster environmental social economic impact main category stand highly relevant support makeitmandatory campaign key stakeholder properly address call mandatory requirement topic align large business financial institution current goal measure performance assess disclose impact define set indicator additionally dependencie biodiversity currently conduct indepth materiality assessment group level order update list material topic identify materiality impact roche impact impact performance material topic support un sdgs society million patient treat roche medicine access healthcare contribute billion test conduct roche product quality well tomorrow diagnostic product safety new molecular entity clinical development digitalisation woman executive position science innovation ethic compliance employee engagement environment decrease environmental impact energy efficiency employee minimise impact nature electricity come sustainable source decrease greenhouse gas emission economy sale invest rd longterm mindset invest medical employee advance create job ensure livelihood cluster material topic detail rochecommateriality strategy focus find new medicine diagnostic different stakeholder healthcare establish databased insight evolve ecosystem broaden access offering practice medicine help patient live people need ultimately long well life provide seamless patient journey continue concentrate energy business environment undergo prescription medicine vitro diagnostic tremendous change face new challenge increasingly datum insight complexity care increase diversify sector like generic pressure healthcare budget biosimilar overthecounter medicine time new opportunity arise major advance life science digitalisation delivery create value healthcare stakeholder partner choice bring significant medical benefit patient doctor turbulent time guide payer offer great place work common purpose patient employee deliver sustainable positive need company bring contribution society earn competitive novel diagnostic treatment patient return investor year patient remain core reason come work day ultimately deliver commitment take people integrity courage passion make difference patient people focus vision fitting treatment proud roche patient provide right therapy right patient ensure good response right leadership inspire outcome matter time right value approach combine embrace diversity inclusion different rich expertise pharmaceutical diagnostic background perspective experience expand datum science capability drive entire organisation foster innovative effective efficient research solution benefit patient way enable well therapeutic decision patient work enable agile networked response everincrease pace change balance pursuit excellence science rest need stability speed flexibility key element exceptionally broad deep understanding disease biology seamless setup design innovation integration capability pharmaceutical autonomous research development centre diagnostic diversity approach alliance external partner maximise innovation longterm orientation foster diversity scientific approach agility global geographical scale reach work partnership party enable attract talent lead global offer integrate solution improve medical science cluster quickly bring solution health economic benefit work people need themour strategy roche focus leadership fitting treatment patient inspire outcome matter distinctiveness way work excellence science agile network delivery setup value stakeholder build innovationdiagnostic commit advance diagnostic solution support healthcare professional make critical decision patient health improve way essential tool integrate health system worldhiro nitta senior scientific fellow tucson usa hiros work roche enable follow passion develop diagnostic address unmet patient need scientific breakthrough impact live million patient worlddiagnostic roche dr bushra jamil professor medicine infectious disease karachi pakistan dr jamil partner stakeholder healthcare system increase access care diagnostic pakistan effort lead provision patientcentric integrate care hiro nittadiagnostic roche steadfast commitment improve access vital diagnostic hiro nitta dedication continually improve accurately diagnose herpositive patient access patient begin world succeed teenager yearold college student japan hiro develop passion aspect begin histology study tissue spend day new diagnostic launch hiros dissect sample analyse datum eventually commitment deepen miss patient publishing finding serve receive lifesave therapy foundation scientist involve develop hiro say new goal develop stateoftheart tissuebase diagnostic precise diagnostic early academic day begin hiros work roche enable follow hiros decadeslong commitment develop passion develop diagnostic address unmet precise diagnostic herpositive patient need create nextgeneration breast cancer patient journey hiro consider test determine specific type life work hiro begin work cell present tumour valuable insight ventana medical system acquire inform new therapy protocol roche today senior scientific eventually enable herpositive patient fellow clinical development medical affair experience well outcome roche diagnostic solution campus tucson arizona plans slow hiro discover previously unknown type time soon hiro explain tumour cell structure work patient s time breast cancer researcher investigate waste type tumour respond targeted therapy time develop test million case breast provide valuable information cancer diagnose globally year fuel obtain diagnostic currently gene herpositive patient available hiros research novel benefit specific target therapy assay evaluate gene determine patient receive protein single tissue sample treatment initially require highly specialised present meeting united states technology woman not right canadian academy pathology treatment challenge test european society medical oncology hiro say not okay access multiple element work ventana hiro dedicated hiro improve access mean cancer develop simple test patient opportunity test conduct lab quickly innovative accurate method breast cancer fact sheet world health organization recommendation human epidermal growth factor receptor testing breast cancer american society clinical oncologycollege american pathologist clinical practice guideline update journal clinical oncology deserve access good cancer diagnostic tool therapie time people love result select point expect survive consider treatment protocol effectively eventual recovery invaluable second save extend live hiro describe chance continue work commitment way patient hiro explain impact experience not matter live money deserve understand fear hope access good cancer diagnostic tool patient feel worry limited treatment therapy time option get second chance live believe people love help goal reality survive work hard continue work develop well cancer patient second chance precise tissuebase cancer diagnostic experience leave drive long great difference inspiration hiro need manage life symptom hiros accomplishment begin long covid remind laboratory know impact work need well testing treatment choice happen outside door hiro find patient cancer treatment facility world meeting research collaborator visit life provide invaluable opportunity connect commit hiro work cancer patient family member interest outside lab awardwinne casual conversation lobby magician perform child hospital hospital help hiro maintain focus paediatric unit raise standard poodle ultimate beneficiary work show competition add love disney talent bake hiro look get know patient people definition wellrounde individual well understand individual journey passionfille life challenge face hope future focus patient hiro explain hiros scientific breakthrough know impact live million patient world commitment reach hiro unique perspective inspire people highly precise diagnostic work march experience lead effective treatment continue dangerously severe covid infection drive daydiagnostic roche quest continuously improve breast cancer diagnosis hiro nitta spend day investigate cancer cell dedicate ensure patient access appropriate treatment option improve understand cancer biology enable access quality care critical diagnostic pakistan grow father physician dr bushra patientcentred care jamil expose practice medicine lack patientcentred system young age read medical book child significant challenge dr jamil see critical instilled love science drive follow gap patient require number different father footstep despite female test send different clinic predominantly maledominate field dr jamil different area basic diagnostic study area medicine pakistan available roof incredibly united kingdom professor inconvenient patient medicine infectious disease aga khan need address university hospital aku karachi pakistan president medical microbiology dr jamil serve national coordinator infectious disease society pakistan mmidsp global fund fight aid tuberculosis malaria grants ministry health diagnostic infrastructure key islamabad procure covid mitigation great deal dr jamil work aku grant focus strengthen health system mmidsp focus increase access quality ensure provision integrate care healthcare pakistan lack effective critical diagnostic roof healthcare delivery system huge challenge type clinical service need pakistan say dr jamil vary country say dr jamil covid province province system extremely serve catalyst funding fragment poor quality urgent ability diagnose infectious disease need invest close gap particularly equipment model relate access diagnostic service truly needle comes adequately train healthcare professional patient care unfortunately covid pandemic exacerbate roche work dr jamil ensure issue bring realisation district level secondary care hospital robust diagnostic infrastructure covid equipped diagnostic system need infectious disease absolutely provide onestopshop approach essential disease diagnose right equipment need use early stage patient eventually effective efficient way possible say dr jamil diagnose define path huge impact case detection especially live rural area followup treatment mention patient private clinic fact easily conveniently need urgent treatment patient greatly benefitdiagnostic roche dr bushra jamil infectious disease expert dr jamil know important role diagnostic play detection treatment disease tuberculosis hiv malaria critical diagnostic infrastructure place dramatically change quality timeliness care patient receivediagnostic roche need able bring diagnostic available affordable simple fast public healthcare system economical manner education key medical education opportunity healthcare important component increase professional execute disease awareness quality care patient pakistan properly education campaign emphasise significance training healthcare professional principle timely diagnosis treatment prevention effective diagnostic management management variety disease area disease workforce inadequately train tend bypass essential step patient look future treat base previous experience ask future look like accurate diagnostic say dr jamil healthcare pakistan dr jamil answer harmful patient treatment clear publicprivate partnership critical base accurate timely diagnostic need able bring diagnostic negative implication community available affordable simple fast country public healthcare system economical manner work train workforce roche diagnostic pakistan partner build diagnostic capability dr jamil mmidsp increase advocacy procedure improve patient journey diagnostic enable improve patient confident implement change access order minimise country disease truly difference live people impact partnership deliver continue pakistan integrate solution improve outcome diagnostic division mark digital pathology portfolio key trend global awareness transform pathology ventana dp value diagnostic aspect highcapacity slide scanner create highresolution healthcare grow significantly covid digital image stain tissue sample help portfolio continue expand meet demand diagnose cancer determine patient relate disease evolution second treatment digital pathology open environment see measurable growth base business allow software developer easily integrate test cancer cardiovascular disease image analysis tool tumour tissue infectious disease advanced upath enterprise software effort build sustainable digital health business set success open digital ecosystem connect innovator digitalise market startup technology leader lab professional clinician researcher preventative screen followup care patient fast access wide range diagnostic play increasingly critical role innovation advance personalise entire patient journey early diagnosis healthcare solution time thousand disease progression slow stop datum point patient create diagnostic testing provide patient family journey help identify change health healthcare professional information enable track similar patient group lead good possible outcome healthcare institution geographie artificial system access diagnostic information intelligence ai machine learn managing disease help avoid unnecessary service eventually allow comparison outcomes delivery reduce overall cost care improve predictive measure effectiveness importantly contribute save life carefully assess diversity patient population diagnostic clinical demonstrate covid pandemic trial demonstrate commitment develop diagnostic information solution solution help improve outcome patient major difference country ability cope world example diagnostic infectious disease outbreak maintain health division contribute meaningful way system advance diagnostic solution support rochewide africa genomics program agp early decisionmake help reduce hospitalisation enable target treatment strategy improve diabetes care advance integrate patient management personalise diabetes management ipdm strategy successfully deploy customer drive innovation digitalisation population insight dashboard streamline building divisionwide digital datum management process enable healthcare foundation strategy portfolio professional administrator payer view advance ambition establish sustainable population level trend time th digital health business unify anniversary mysugr patientcentric interface digital health portfolio navify core open ecosystem introduce brand provide range nextgeneration extend functionality expand smartphone software solution compatibility mysugr pump controldiagnostic roche test conduct roche diagnostic product billion cobas system instal inception active inlicense agreement active outlicensing agreement diagnostic fact covid test enable month million covid key launch launch date approval indicationdisease etc systemplatform covid variant test march research use sarscov b variant omicron subvariant cobas ba ba ba ba ba delta lightcycler cobas z depend test cobas sarscov duo test june fda emergency sarscov rna nasal nasopharyngeal cobas use authorization swab specimen elecsys igra sarscov test august ce mark support understand immune response cobas e e sarscov infection vaccination e e analyser sarscov rapid antigen test october ce mark sarscov test deliver reliable result instrument need minute sarscov rapid antigen test nasal sarscov antigen self test nasal cobas sarscov qualitative test october fda covid pcr test perform cobas highthroughput platform new platform test digital solution pathology lab roche information solution new platform new digital solution new test new digital solution diagnostic point care key launch molecular lab new test new platform new test diabetes care core lab new digital solution new platform new test new digital solution cancer key launch launch date approval indicationdisease etc systemplatform cobas hpv test june ce mark selfsample human papillomavirus hpv screen cobas molecular selfs ample solution prevent cervical cancer instrument ventana dp june ce mark create highresolution digital image stain tissue slide scanner sample help diagnose cancer digital pathology portfolio benchmark ultra plus june ce mark global fully automate tissuestaining process new system ventana mmr rxdx panel august fda label companion diagnostic solid tumour treat benchmark ultra expansion merck immunotherapy keytruda digital lightcycler system august country worldwide nextgeneration digital pcr system help clinical new system cemarke fda researcher well understand nature patient k exempt status cancer genetic disease infection pathway antiher october fda companion diagnostic assessment benchmark ultra ihcish b test low status metastatic breast cancer patient slidestaine instrument prame epr antibody october na evaluate prame protein expression patient benchmark ultra ihcish suspect melanoma instrument ventana folr folr november fda immunohistochemistry companion diagnostic aid benchmark ultra rxdx assay identify epithelial ovarian cancer patient eligible target treatment elahere immunogendiagnostic roche key launch launch date approval indicationdisease etc systemplatform cobas infinity edge january rolling launch cloudbase platform connect patient test result module unite select market medical record thirdparty application scribe smart cobas pulse january ce mark blood glucose management solution mobile handheld blood glucose digital health capability management device floodlight january mdr certification smartphone app enable datadriven smartphone decisionmake patient multiple sclerosis mysugr pump control april launch allow diabetes patient import temporary basal accuchek insight select market rate accuchek insight insulin pump insulin pump mysugr app lightmix modular virus available research mpox virus detection lightcycler ii kits quantitative pcr test use majority instrument country worldwide cobas z analyzer elecsy hcv duo immunoassay july ce mark simultaneous independent determination cobas e cobas hepatitis c virus antigen antibody status e immunoassay single human plasma serum sample analyser elecsys amyloid plasma panel july fda breakthrough device detect measure alzheimer disease biomarker elecsys technology designation blood plasma cobas pure integrate solution september fda generation innovation cobas family cobas pure serum work area solution cobas mpxv november fda emergency pcr test qualitative detection dna cobas use authorization mpox virus elecsys ad csf assays december fda cerebrospinal fluid assay support accurate cobas fully automate timely diagnosis immunoassay analyserspharmaceutical proof scientific innovation lead product truly save improve patient live focus oncology immunology ophthalmology infectious disease neuroscience metabolic rare disease translate excellence science effective medicine patientsfrankline akinyi otieno breast cancer patient kenya east africa frankline receive treatment breast cancer national access programme kenya programme important step kenyan woman breast cancer access standardofcare treatmentpharmaceutical roche ricky alas global value stream strategy lead basel switzerland ricky team work improve patient receive healthcare access medicine work result new transformative way provide direct topatient treatment delivery home care service frankline akinyi otienopharmaceutical roche overcome challenge access breast cancer treatment kenya peer educator centre health wellbeing face stigma solution facility ukwala town kenya frankline family friend colleague amplify akinyi otieno work woman educate concern tell cancer expensive support range health issue people not survive chemotherapy past year visit woman community speak reproductive family difficult time accept sexual health include topic sexually cancer diagnosis concern transmit infection family planning frankline medical treatment insisting educate woman perform breast try herbal medicine frankline selfexamination encourage reservation try option month cervical cancer screening ultimately herbal medicine not work frankline return jootrh proceed role require extensive knowledge recommend treatment plan doctor topic frankline learn long ago importance selfexamination confront access challenge screen observe poster hospital frankline undergo mastectomy follow visit frequently asthma cycle chemotherapy impact routinely perform breast selfexamination life significant easy prove critically important practice journey say surgery life find lump not comfortable get sick chemotherapy arm frankline immediately consult doctor constrain surgery not lift heavy refer specialist jaramogi oginga object hang clothe dry line sleep odinga teach referral hospital jootrh right people start see differently investigation follow ultrasound selfesteem suffer result mammogram biopsy frankline tell breast cancer follow surgery chemotherapy frankline continue hormonal explore alternative treatment option treatment treatment cover huge shock hear breast national health insurance fund nhif cancer recall not expect point face difficult breastfeed time prior decision nhif cover mastectomy test indicate lump chemotherapy hormonal normal tell subside time treatment need pay remain treatment frankline explain hear diagnosis frankline hesitant not afford not know follow recommend hospital treatment stuck stop treatment afraid potential effect month weigh option want advocate woman screen early well right diagnosis treatment soon frankline answer june bright future ministry health kenya nhif roche frankline thankful able announce partnership breast cancer access treatment recognise treatment available nhif members kenya importance knowledge impact national access programme screening selfexamination save life cancer medicine kenya important step say want advocate woman ease financial burden kenyan woman screen early well breast cancer ensure access right diagnosis treatment cancer not standardofcare treatment death sentence long diagnosis early breast cancer commonly diagnose cancer kenya case diagnose today frankline respond year breast cancerrelate treatment optimistic death partnership roche future hold believe dream helping strengthen diagnostic ecosystem future plan live breast cancer screen early diagnosis normal life say patient improve referral pathway treatment centre woman big future help son treatment need timely manner realise dream son comfort sick tell frankline welcome news mean want well say frankline worry pay pocket want pilot grow continue treatment hope help education know easy live happen fly treatment cover world cancer global stage incidence cancerrelate mortality kenya world health organization region africa asco postpharmaceutical roche like woman breast cancer kenya frankline face financial challenge prevent get medicine need new collaboration ministry health kenya nhif roche breast cancer treatment available make easy accessible woman like frankline receive standardofcare treatment frankline look forward bright future son improve access treatment patient comfort home ricky alas work consultant digital delivery specialty medicine uncommon innovation corporate venture building significant improvement san francisco expose number patient quality life industrie range financial service potential save healthcare cost consumer package good year efficient process delivery treatment ricky ready change industry d work draw healthcare ricky global idp team initially want organisation tasked finding way home delivery direct tangible impact improve people evrysdi oral treatment spinal muscular life join genentech digital atrophy sma reality small feat consider transformation lead global supply chain like exist medicine typically pick specialty shortly settle ricky give treatment centre hour opportunity work project call integrate patient home set create solution direct delivery patient idp desirable patient ecosystem value patient clear idp stem feasible viable accord ricky feel exercise answer question like startup time healthcare system look like design build new business establish patient family member company roche opportunity need want amazing life think roche ambition provide initial thinking improve benefit patient cost society idp process healthcare delivery well support exactly say ricky m proud work patient caregiver simplify organisation ambitious goal treatment key solution point direct come new creative idea topatient delivery home care service achieve not know work idp bear successful project try find way improve improve quality healthcare service people live patient family member alleviate hospital clinic burden reduce number inperson programme launch patient visit improve outcome patient interest office world participate great convenience potentially well overwhelmingly positive road treatment adherence ahead challenging team forge new path direction legal regulatory meeting patient requirement supply logistic solution home delivery consumer good pizza take account stakeholder need appliance everyday life home preference unknown andpharmaceutical roche ricky alas ricky idp team work colleague globe design develop implement tailor programme enable delivery treatment directly patient home convenient solution save countless hour travel time specialty hospital patient rare chronic condition like sma haemophilia caregiver lifechangingpharmaceutical roche believe evolution healthcare go continue patientcentric realm unconstrained space recall ricky significant impact improve patient road map industry barometer success live ricky enjoy project figure go hit relationship s form feel like ve roadblock amplify genuinely friend ve meet look despite challenge person think comes idp see significant growth increase get meaningful work cool way initial launch pilot programme dedicated people year programme roche affiliate globe trailblaze new path access idp show sign slow idp successful people affiliate continue join project create ricky say hesitation lead fitforpurpose directtopatient project respective country outofhospital solution fact ricky hopeful involve daytoday work overcame serve future capability constraint step way project roche pipeline product not not possible passion initiative world talk idp drive single goal address project long way unmet need patient demonstrate value medicine patient ecosystem collaboration border local team come design ricky think roche play role help deploy solution collaboration ecosystem ecosystem adapt establish necessary partner power resource capability enhance access firmly place idp network ricky feel fortunate patient heart believe get work colleague evolution healthcare go continue country diverse perspective patientcentric realm say idp crossfunctional background level begin s project work try help trigger transformation find solution challenge explain recently relocate basel wife young child ricky excited continue clear ricky passionate play idp excited meet make difference people idp friend s way clear commitment innovation commitment innovation clinical decline people early alzheimer clear past year major disease roche remain committed disease investment research development complex neurological disorder unique combination autonomous major public health challenge independent research organisation continue develop deliver test enable investment strong network early accurate diagnosis pipeline external partner organisation globally investigational medicine different target drive pioneer scientific technological type stage disease breakthrough healthcare power partnership launch vabysmo bispecific facilitate patient access quality medicine antibody approve eye target heart business meet rise global inhibit signal pathway link demand highquality accessible healthcare number visionthreatene retinal condition service integrate comprehensive neutralise angiopoietin ang vascular actionable plan work enhance endothelial growth factora vegfa vabysmo patient partnership worldwide approve country world include united states japan enter partnership united kingdom european union holistic approach improve population health people live neovascular wet agerelate international federation red cross macular degeneration diabetic macular red crescent societies ifrc collaboration oedema review regulatory authority help unlock access previously underserve ongoing continue pioneer new way population worldwide strengthen treat visionthreatene eye disease commitment meet need patient matter live european commission approve polivy combination previously untreated diffuse large advance inclusive research bcell lymphoma dlbcl firstinclass deeply commit address barrier bispecific antibody lunsumio treatment clinical trial participation advance inclusive relapse refractory follicular lymphoma research believe improve health outcome lunsumio represent new type immunotherapy patient core mission chemotherapyfree fixedduration commit industry leader offer treatment option potential provide patient lifethreatening disease durable remission offer significant period chance receive investigational medicine time treatment follow initial therapy polivy combination treatment option aim continuously evolve process year clinically meaningful improve accessibility convenience ultimately improvement progressionfree survival adherence lead well outcome patient approve eu patient previously reduce burden caregiver order untreated dlbcl meet unique requirement country global country colleague work closely phase iii graduate ii trial external stakeholder extra meet primary endpoint slow mile patientspharmaceutical roche pharmaceutical clinical pipeline phase phase ii phase iii registration oncology inflammationimmunology neuroscience infectious disease ophthalmology metabolic pipeline new molecular entity cover broad range disease highly innovative technology apply create produce active molecule new partnership product outlicense agreement divestment acquisition phc agreement product technology discovery number new licence agreement partnership research discovery collaboration agreement derive exist alliance pharmaceutical roche major approval china europe ctemraroactemra l unsumio rheumatoid arthritis subcutaneous follicular lymphoma thirdline treatment rozlytrek polivy ntrkpositive solid tumour diffuse large bcell lymphoma firstline treatment rozlytrek major approval rospositive nonsmall cell lung cancer tecentriq nonsmall cell lung cancer adjuvant therapy tecentriq nonsmall cell lung cancer adjuvant therapy v abysmo diabetic macular oedema v abysmo neovascular wet agerelate macular japan chugai degeneration ctemraroactemra covid pneumonia ctemraroactemra g azyvagazyvaro covid pneumonia chronic lymphocytic leukaemia firstline treatment ctemraroactemra h emlibra giant cell arteritis intravenous acquire haemophilia c otellic perjeta herceptin histiocytosis herpositive colorectal cancer l unsumio p olivy follicular lymphoma thirdline treatment diffuse large bcell lymphoma firstline treatment tecentriq tecentriq alveolar soft sarcoma nonsmall cell lung cancer adjuvant therapy evrysdi abtherarituxan spinal muscular atrophy presymptomatic paediatric month neuromyelitis optica spectrum disorder v abysmo v abysmo diabetic macular oedema diabetic macular oedema v abysmo v abysmo neovascular wet agerelate macular degeneration neovascular wet agerelate macular degeneration xofluza influenza paediatric oncologyhaematology inflammationimmunology neuroscience infectious disease ophthalmologypersonalise healthcare year helped lay scientific groundwork personalise healthcare treatment target underlie biology cancer disease work take personalise healthcare future care tailor individual need unique genetic profile un sdgs material topic patient centricity rd efficiency personalise healthcare realworld data preparedness age societysusanne frstmichna cancer unknown primary cup patient sinntal germany susanne diagnose cancer unknown primary cup early opportunity receive tailor treatment plan inform comprehensive genomic profiling cgppersonalise healthcare roche dr konstantinos balaskas medical ophthalmologist london united kingdom dr balaskas team moorfield eye hospital utilise remote vision monitor patient retinal disease ambition empower assume great ownership management health susanne frstmichnapersonalise healthcare roche comprehensive genomic profiling bring new hope fight rare cancer march drive home example lung breast job frankfurt germany susanne frstmichna patient cup treat standard casually touch neck find chemotherapy unfortunately prognosis poor lump return home median survival follow diagnosis evening contact physician friend month recommend consult specialist begin journey imagine susanne concern step face unknown think go deal unfortunately number visit different specialist happen height susanne tell wrong covid pandemic susanne kidney function subsequent ct scan attend appointment clinic near reveal large number swollen lymph nodes home hard husband suspect lymphoma support allow pick remember day scan son susanne recall final th birthday susanne recall day consultation doctor allow celebrate take turn ask option worst urologist call move forward moment evening anxious day forget family doctor tell cancer needless stunned path forward susanne doctor recommend elusive diagnosis care specialist heidelberg testing lymph node drive heidelberg heavy heart result reveal cancer originate return completely different people ask mean oncologist say say get car head home cancer unknown primary cup say confidence restore susanne soon get home start research online like day appointment susanne tell learn scary type cancer option potentially receive original tumour find personalised treatment plan technology doctor able find secondary tumour analyse dna patient metastasis spread result primary technology call comprehensive genomic profiling cgp way find unique cancer diagnose cup fingerprint cancer tumour help absence primary tumour cause practical determine specific genomic alteration problem traditional treatment approach target molecularly guide rely know site cancer origin therapy cancer immunotherapy approach understand cancer secret syndrome new scientist genomic testing foundation medicine inc change doctor say target drug treat specific alteration d able control represent shift treat cancer base dedicated plus husband site likely site origin treat patient time talk laugh think like susanne base clinically relevant future susanne say susanne genomic change suspect drive cancer able continue work growth provide complete picture husband find new passion mountain susanne cancer cgp help inform bike scenic road near home tailor treatment plan potentially remove different route day end need determine cancer original location place ve body team doctor describe wonderful say excitement opportunity know seize voice opportunity recall susanne positive outlook personalise treatment plan susanne feel incredibly lucky susanne undergo cgp test evaluate opportunity receive personalise treatment gene know associated cancer growth plan inform cgp impact cgp answer provide essential step constantly evolve diagnostic tool develop informed treatment strategy solution improve target therapy august susanne thrill developed datum generate tell cgp reveal genomic alteration improve understand cancer biology drive cancer growth susanne husband son change cup doctor daughter plan holiday say target drug treat united states spend time specific alteration d able travel enjoy company control good gift anybody m live life like travel give point say susanne closeknit family not allow change life negative soon susanne cancer alteration thing course deal illness identify personalise treatment begin think positively travel heidelberg week basic principle say susanne ve give receive therapy clinic grateful gift see kid grow adulthood husband company car ride spend time husband time team wonderful continue enjoy lifepersonalise healthcare roche diagnose cancer unknown primary susanne unsure future hold utilise comprehensive genomic profiling determine personalise treatment plan hopeful future family continue enjoy time explore scenic landscape near home sinntal germany digital health solution transform care live progressive eye disease ophthalmologist dr konstantinos balaskas urgent need remote vision monitor firm believer old adage eye conjunction regular office visit quickly window soul interest ocular result moorfields roche partnering medicine begin medical study pilot programme address problem athens greece lead current role retinal specialist principal investigator collaboration roche begin research artificial intelligence digital necessity week deploy technology moorfield eye hospital programme continue develop london united kingdom offer moorfields medical retina clinic say dr balaskas dr balaskas credit keen interest field ophthalmology fact constantly propose solution app call home evolve ve like ophthalmology vision monitor patient chronic eye instinctively dramatic rapid technology disease download smartphone transformation revolutionise way tablet monitor vision comfort provide care patient say year home patient app year area constantly reinvent perform visual function test test result able treat disease eye instantly available clinician view incurable change patient test result practitioner notify follow goal prevent vision loss especially patient directly retinal disease say dr balaskas long ago diagnosis chronic retinal disease register approximately patient devastate patient absence home monitoring service ambition effective treatment recently empower assume great ownership hope improve quality life patient management health reflect dr balaskas digital technology great access care future potentially allow change landscape care monitor away hospital assume type remote close home monitoring create great distance clinician patient dr balaskas urgent need rapid solution say opposite true fact datum generate april early stage covid home vision monitor help inform pandemic dr balaskas colleague know enrich discussion physician need urgent solution patient patient experience greatly impact retinal disease fall highrisk population relationship patient positive develop illness covid way actually bring close avoid hospital attendance infuse sense reassurance beingpersonalise healthcare roche dr konstantinos balaskas thank technological advancement treatment retinal disease hope quality life patient improve potential allow monitor away hospital close homepersonalise healthcare roche hope programme enable provide care right patient right place right time monitor regularly say patient medical association possibility maintain regular appointment scale instigate discussion potential home vision monitor future conjunction regular office visit remote roche team plan limited monitor programme potential reduce product release united states expand burden hospital visit patient pilot uk healthcare system hope programme enable provide care dr balaskas possibility technology right patient right place right artificial intelligence time say dr balaskas chronic retinal disease decision support system telemedicine well prognosis early diagnose virtual clinic way future treatment start longterm benefit aspiration hope able healthcare system delivery integrate approach innovative sustainable care home vision monitor solution integration key materialising currently aid diagnosis retinal disease benefit technology say help identify change vision time put enable well aid physicians clinical access quality care patient future decisionmake meantime dr balaskas team learn future celebrate recent win health initiative kind service journal patient safety award home ophthalmology attract significant vision monitor app award good virtual attention international remote care initiative great retinal community learning barrier moment true testament innovation enabler deploy home vision monitor collaboration patientcentric approach recently publish journal american dr balaskas say proudly tailor care personal todays convergence pioneer science delivery enable longterm access advanced technology datum analytic sustainability resiliency shift healthcare onesizefitsall approach delivery patientcentred aim catalyst contributor care tailor care solution commonly holistic thinking crosssector collaboration personalise healthcare enable collective effort necessary turn personalise roche truly integrate holistic care experience care reality people society spans prevention detection diagnosis treatment ongoing monitoring care partner healthcare ecosystem individual people essential designing testing implement new personalise solution improve health insight personalise care individual enable healthcare professional highquality datum analytic engine confident healthcare decision drive personalise healthcare today reduce cost burden society today healthcare system produce wealth untapped roche partner effort span pharma information feed diverse health datum biotech company startup nongovernmental individual generate life organisation healthcare provider government datum yield valuable insight allow regulatory authority patient community early prevention identify pattern trend academia technology company population health managing disease personalise way find tumour fingerprint cancer disease genome drive roche wide range diagnostic information genomic alteration comprehensive genomic solution generate manage billion datum profile cgp type cancer genomic testing point year contain highquality help find unique fingerprint information potential trigger patient cancer tumour help determine advance personalise healthcare take behave grow contribute significantly longitudinal datum provide comprehensive picture roche foundation medicine patient help support healthcare professional work advance cancer care research decisionmake clinical decision embed cgp care continuum support tool point care cgp inform easy fast well clinical decision cgp drive partnership collaboration fast efficient rd insight personalise healthcare aim transform generate help optimise clinical trial design care seamless individualised experience support development effective patient need transform care target treatmentspersonalised healthcare roche flatironauthore publication twentythree flatironauthore paper accept publish peerreviewe patient profile journal link patient profile foundation medicine flatiron health clinicogenomic database cgdb new molecular profiling flatiron health new molecular profiling integration milestone caris life sciences foundation medicine international expansion flatironauthore poster discussion international expansion focus transform global oncology research care subsidiary fourteen accept flatironauthored poster japan germany united kingdom discussion presentation showcase flatiron scientific leadership key industry conference million clinical report breakthrough device designation million report deliver breakthrough device designation receive foundationone portfolio comprehensive foundationone tracker circulate genomic profiling cgp tests tumour dna ctdna detection molecular monitoring assay foundation medicine milestone partnership epic patient profile customer partnership link patient profile epic electronic medical record emr foundation medicine flatiron health system go live clinicogenomic database cgdbaccess healthcare working collaboration global local stakeholder support government effort build strong resilient healthcare system particularly people low lowermiddleincome country countrys healthcare system unique work closely partner develop deliver tailor solution un sdgs material topic longterm mindset availability healthcaredr eric ngyedu chief executive officer cape coast teaching hospital cape coast ghana newly open cancer treatment centre ghana dr ngyedu focus addressing challenge cancer patient face journey grateful power partnership directly benefit patientsaccess healthcare roche dr roberto altamirano gynaecologic oncologist santiago chile dr altamirano play key role advise ministry health chile evolution hpv testing cervical cancer screen critical prevention strategy important step eradicate disease country dr eric ngyeduaccess healthcare roche breaking barrier cancer care ghana dr eric ngyedus career spend country partnership great deal time effort improve start address geographic access health people ghana training barrier quality cancer care support capacity oral maxillofacial surgeon santa building training healthcare worker clara cuba dr ngyedu return home ghana support awareness creation community soon find country big impact community deliver improve care ghanaian cancer centre open public hospital ghana mandate today dr ngyedu chief executive officer provide cancer service facility cape coast teaching hospital ccth overburden lead delay patient west coast ghana hospital world access specialised care say dr ngyedu class leader tertiary healthcare bode manage outcome medical research serve train ground worsens patient prognosis financial hardship undergraduate postgraduate training present long travel worsen plight medical health professional patient know crucial curb hospital site new cancer challenge establish new centre treatment centre cancer service patient outside region significant public health challenge ghana new case diagnose centre provide infrastructure people die disease space oncology patient treat treatment oncology pharmacy ghanaian face numerous challenge cold room establish support patient journey include health mental provision quality medicine reagent social financial hurdle explain dr ngyedu diagnosis treatment limited infrastructure limit access comprehensive treatment centre limit unique partnership access affordable cancer medicine roche long work improve oncology challenge mean patient care ghana dr ngyedu grateful experience harrowing journey partnership like directly benefit patient partnership roche unique address significant public health patientcentred challenge product support patient care thank partnership roche break barrier cancer patient face government ghana work begin develop say private sector critical role infrastructure deliver cancer care key play increase access care people hospital country ccth ghana need partnership like new treatment centre open needle meaningful change international agency research cancer world health organization ghana fact sheet partnership roche unique patientcentred product support patient care break barrier meaningful change partnership large portion population life bring increase screen remote area need find way provide treatment breast cancer patient year care telemedicine absolutely possible breast cancer awareness month october care cancer patient distance able screen people breast need technology place partnership cancer support receive private sector help roche provide infrastructure today continue able cost patient say future look role technology dr ngyedu additionally roche working play government enable public funding key cancer treatment testament roche longterm commitment impact partnership ghana african continent continue invest strengthen health system sustainable future collaborate partner implement innovative tide begin turn patient solution tailor specific need ghana opportunity patient region dr ngyedu bring pave way increase access care hope future healthcare ghana future leverage technology provide care patient centre cancer patient critical reflect dr ngyedu right thingaccess healthcare roche cape coast teaching hospital home new cancer treatment centre increase access screen treatment patient ghana dr ngyedu believe cancer care continue evolve thank new technology partnership private sector lead critical evolution cervical cancer prevention chile life dr roberto altamirano evolution improve prevention understand importance good health cervical cancer guideline evolve passionate help people make year critical milestone difference passion lead achieve ministry health chile medicine specifically gynaecologic oncology introduce pilot project implement hpv want surgeon test health service want treat patient good health system need person main goal help upgrade pap test limitation impact community say dr altamirano recently dr altamirano significant advisor ministry progress goal play role advocate hpv testing year ve change health system improve put forward explain cervical cancer screening chile start work mentor improve health system share vision longstanding process screen help people possible good way chile national cervical change conduct screen cancer screening programme pap enable well prevention persistent test standard identify woman need hpv testing risk programme reduce mortality rate time woman continue diagnose chile country move preventable disease suggest screen programme hpv primary not effective early detection test eligible woman line world health cervical cancer organization recommendation case woman not kind screening strategy aim well identify test miss opportunity prevention risk disease order prevent invasive cancer explain dr altamirano develop despite preventable overcome barrier adoption vaccination screen treatment cervical programme introduce cancer claim live woman barrier prevent woman year make lead cause screen say dr altamirano big cancer death woman human papillomavirus hpv problem lot woman not test know cause nearly case cervical think not need not cancer finding treat precancerous time think go hurt disease cancer develop important opportunity screening miss prevention strategy cervical cancer fact sheet world health organization cervical cancer screen individual average risk guideline update american cancer society implementacin del diagnstico molecular del vph experiencia chilena en curso revista mdica de chile global strategy accelerate elimination cervical cancer public health problem world health organizationaccess healthcare roche dr roberto altamirano dr roberto altamirano key advocate pilot programme chile emphasise hpv testing primary screening method eligible woman important strategy prevent cervical cancer continue mission raise awareness education hpv importance cervical cancer screen woman power knowledge care themselvesaccess healthcare roche believe well give people power knowledge care need increase awareness hpv screen woman year teach patient importance prevention relatively confident woman say education critical patient negative hpv test low risk develop healthcare professional cervical cancer focus ensure not comfortable talk hpv woman screened identify accustomed pap test high risk addition provide hpv test health believe programme critical service pilot programme roche work step help country meet s goal partner train primary healthcare eradicate cervical cancer century provider collect sample support m dreamer try stay positive education programme increase awareness think go work say hpv importance screening change need time insist prevention dr altamirano believe crucial day right thing help bring healthcare professional board achieve goal eliminate disease new screening method explain go teach programme ongoing thirst knowledge learn perform hpv test adapt today dr altamirano entrenched chilean change health system selfproclaime multitasker practise gynaecologic oncologist public see impact patient private healthcare member education woman chilean society obstetric gynaecology start ask test people advisor ministry health recently involve seek information start expand knowledge area earn know hpv masters health administration assistant professor obstetric gynaecology chile national ambition university chile today woman screen programme ministry health remain committed goal plan expand hpv testing health service help year chile ultimate goal achieve national experience passionate access eligible woman educate patient generation gynaecologic oncologist believe dr altamirano think hpv testing place well give people power knowledge woman reach hpv test care year mean not power partnership roche know diagnostic nordisk global local partner medicine positively impact live publicprivate partnership reach reach people need child country country unique challenge tunisia vietnam join project come access healthcare vary dramatically country country initiative increase access medicine funding infrastructure healthcare capacity low lowermiddleincome country disease awareness play role delight renew long firmly believe need holistic standing partnership world federation collaborative approach address potential hemophilia partnership barrier challenge simply complex patient haemophilia low single party solve lowermiddleincome country reach aid programme addition hundreds increase access diagnostic healthcare professional train world testing capacity enable expand past decade publicprivate partnership strengthen laboratory additionally proud system african nation highly impact member access oncology medicine hivaid build institutional capacity atom coalition new global partnership lead regional national partner improve union international cancer control quality diagnostic service continent increase access qualityassure essential effort improve million cancer medicine low lowermiddleincome life example work partnership country help country develop president emergency plan aid capacity proper use include training relief pepfar scale hiv viral load testing diagnostic partnership complement early infant diagnosis exist goal double number patient enter new partnership global fund receive innovative therapy low build local capacity tackle fundamental lowermiddleincome country end infrastructure challenge generate goal aims overcome barrier deliver diagnostic result manage patient face lowincome country healthcare waste lack infrastructure economic pressure regulatory challenge address diabete access barrier disparitie worldwide small summary initiative publicprivate partnership critical develop work expand access healthcare sustainable access initiative world partnership sit see diabete heart access work partner roche play address continue work closely public private diabetes access barrier disparitie worldwide nongovernmental organisation broaden change diabetes child access healthcare diagnostic programme run roche diabetes care novo medicinesaccess healthcare roche million hivpositive patient child able viral load monitor country reach global access program check change diabete child programme treatment efficacy partnership novo nordisk launch people patient screen diabete low lowermiddleincome country year meru kenya mwanga access core medicine access project access project billion test roche rank th world conduct roche worldwide access diagnostic product medicine index woman people low lowermiddleincome country help year genentech access screen cervical cancer medicine need free medicine support roche global access program provide people double compare city million people continue work city cancer challenge roche patient support programme active city worldwide reach increase estimate million peoplepeople culture believe personalise approach achieve good outcome patient true employee strive identify create opportunity unique cultivate environment enable people bring unique self roche achieve good work behalf patient un sdgs material topic talent attraction retention organisational agility patient centricitycris wilbur chief people officer basel switzerland cris believe employee align share purpose feel comfortable sharing view support resource need truly difference live patientspeople culture roche lorice scalise general manager roche pharmaceutical buenos aire argentina leader lorice understand increase access healthcare begin understand value diversity individual require roche leadership workforce reflect diversity cris wilburpeople culture roche help team patient centre cris wilbur roche chief people officer effectively go able firm believer roche employee play bring solution fast patient customer critical role shaping foster right culture order meet commitment patient end goal mind roche different division operate principle solely patient operate different geography well spotlight clear sense share vision commitment make patient focal purpose point cris explain time corporate executive operating principle say committee realise important patient make clear opportunity develop align principle expect single person company reflect unique roche culture say patient mind empower entire company remain focused manifest thing innovation making focus understand need difference patient society begin roche group operating principle bear integrate company culture process create principle worthwhile journey clear focus ensure operate principle seemingly simple positive impact large culture statement goal guide work roche nice company cris explain different part organisation s important incredible thing lot mean thought like individual principle set principle operate principle enable supportive bring require input feel comfortable colleague organisation ensure bring different view debate principle resonate people foster innovation quickly inspire challenge think work new way cris add help hold accountable well teammate privilege process say colleague partner enable people cris organisation transforming bring self conversation agile working celebrate okay differently need come agree disagree colleague single set principle look like truly embrace difference practice ultimately able work integral culture patient mind manifest thing focus understand need begin align future ambition ask colleague simplify roche longterm ambition drive work radically project think day operate principle serve longterm see critical tool goal reality principle truly help prioritise set clear help different part organisation work area focus work share effectively big purpose say cris tremendously sustainable impact principle help inspiring innovative collaborative company lose sight big goal surprise passion cris say outside work criss interest include quantum computing reinforce belief principle place longevity continuous improvement focus future mind not want way work find potential fascinating try constantly change say cris sense new development cris say quantum permanence enable people company computing help solve big develop approach work firmly root problem improve supply chain logistic share purpose share way work accurately forecast weather confident track long time able help greatly reduce time cost come need develop new drug month follow rollout operate future look like cris principle clear people begin confident increasingly complex world live common hear colleague roche remain focused right thingspeople culture roche culture roche centre share purpose make meaningful difference patient society new operating principle unite employee work achieve goal embrace uniqueness individual leader unique patient serve spend minute lorice scalise overcome bias explain general manager roche pharmaceutical able everyone argentina immediately sense achievement clearly lorice conversation passion people passion turn point make lorice exceptional leader effective advocate improve access healthcare new focus diversity inclusion enable lorice understand success expand lorice stop put energy access begin understand value person think expect diversity individual requires comfortable simply roche leadership reflect diversity newfound freedom effective job explains realise year roche lorice trust connect emotion witness substantial increase intuition work see company commitment build diverse potential blocking take step inclusive leadership culture remove obstacle way see commitment well equip company meet diverse need vast company approach diversity world patient inclusion evolve significantly today talk new level lorice say evolution impact lorice leadership know not consider different style roche decide focus perspective people involve work diverse inclusive empower include cultural economic religious aspect bring true self work change effectively serve purpose help way leadership position view patient mission work live day important seat table initial hesitancy lorice genuine passion listen roche announce commitment truly interested increase number woman leadership quality critical member lorice shock emphatically explain roche diversity inclusion di council not want quota want di council great achievement value achievement gender explain latin american region underrepresented initial effort place people roche ceo severin schwan visit brazil lorice share concern severin say di council focus range understand feeling need initiative include increase talent pipeline change company begin underrepresented country make clinicalpeople culture roche lorice scalise leader lorice understand increase access healthcare begin understand value diversity individual require roche leadership workforce reflect diversitypeople culture roche late innovation regulatory approval remove barrier include social cultural economic trial inclusive increase health equity screen hpv virus cause woman take seat commit give cervical cancer clear example know voice underrepresented country people reason woman place lorice say m share thought unable unwilling physician lorice help challenge status quo broaden say determined help protect company perspective woman cancer need develop selfadministered hpv test pay attention unique aspect culture course lorice understand obstacle serve understand specific fully diverse inclusive leadership exist type innovation need lorice caution belief goal believe roche responsibility lead declaration place company mission expand healthcare access people necessary groundwork know part world understand subject situation different need biology culture change new reaction treatment thing learn understand lorice explain lead example finally lorice seek dispel belief lorice commitment improve diversity diversity inclusion simply different inclusion roche deeply rooted word thing explain personal belief walk walk explain distinction diverse group m single mom boy giri take people place culture english class age ask feedback different belief not value accept work hard development idea discount help mentor living proof not speak perfect english example overcome barrier bias inclusive diversity step inclusion vital lorice equally passionate life outside second step office wake morning excited day bring say family connect access diversity friend ground confidence lorice firmly believe science innovation fight battle cheer achieve purpose reach s lead charge diverse late inclusive workforce office innovation regulatory approval explain find adventure kid remove barrier include social lose book explore new world cultural economic unique individual support engage people year leave mark multiple way global live team know finally overcome pandemic move important care endemic state allow start care global return spending time office live programme focus mental health possible time new challenge guide theme year reveal form political tension dedicate wellbeing day offer covering conflict different part world different aspect mental health include inflation potential energy shortage europe boost energy mindfulness resilience mental health awareness neurodiversity run biyearly global gratefulness employee opinion survey geo measure engage happy employee work lead learning cycle continue check networked way work require workforce sense engagement effort build capability lead learn move right direction include foremost selfleadership approximately small large affiliate learn mindset roche employee roche conduct regular geo pulse survey globally complete hour learn please continued engagement train internal learn platform activity pay people happy work roche despite challenge addition imply safe environment face year culture base shared set value leadership commitment collaboration framework carry livingwage analysis underpin purpose february country roche operates launch new global set operating analysis show country roche pay principle define work employee live wage achieve longterm ambition single set continue regularly monitor future principle extremely receive employee replace divisional ongoing focus safety wellbee functional principle previously develop people purpose centre serve patient continue support society employer care leader employee enhance advance people safety wellbee especially leadership skill time escalate political threat conflict dedicate leadership programme employee assistance invest curriculum senior leadership programme place special focus programme prepare launch manage mental stress health offer symbiosis sequel kinesis synergy financial support employee conflict region early people culture roche employee region north america asia parttime africa australianew zealand fulltime latin america europe pharmaceuticals pharmaceutical diagnostic diagnostic corporate group function chugai chugai employee divisionodg training hour supervisory organisation employee health safety total number lose time incident lose time incident frequency rate number employee express fulltime equivalent operate divisional group business unit department diversity inclusion personal diversity inclusion di heart target achieve share roche strategy deliver personalise care woman executive position patient world start represent nationality executive position embrace unique power person transform live patient ensure society individual roche role play good work thrive roche place people accept address unmet need diverse patient compromise true self community embrace different way working style focus di patient pillar leadership driver innovation expansion advance inclusive research provide wide range learn opportunitie air practice principle company di accessible employee support public position statement world employee air expand inclusive research participate site alliance strengthen partnership healthcare provider community addition external pledge embed inclusive research heart roche signal commitment development life cycle team improve health inclusive culture sign valuable pledge outcome patient core purpose support disability inclusion workplace increasingly diverse world time commitment different dimension diversity research clinical development strength inclusive culture empower ensure great inclusion racial ethnic collective effort diversity group support optimise health outcome network roche come drive di patient worldwide vision forward building workforce reflect society advance positive change society serve believe ability advance positive change achieve purpose require ability society go far business sustainably creative leverage broad spectrum enable equitable access science idea bring meaningful solution technology engineering mathematic stem patient healthcare ecosystem opportunitie realworld science biotech effort people pillar focus skill hope help grow generation achieve representation global society innovator invest partner employee represent community diverse company share commitment di foster great equity society scale positive change topic di essential achieve longterm society far roche healthcare ambition include diversity leadership building equitable diverse inclusive mirror workforce globally set future allpeople culture roche global di corporate goal set target achieve share woman executive position underrepresented nationality executive position q baseline additionally invite leader roche additional commitment relevant local culture context woman underrepresented nationality q q q q q q q q goal diversity network chapter globe agegeneration raceethnicity disability gender lgbtq di veteran intersectional diversity network grassroots selforganised group employee come contribute di mission organisation specifically aim embrace unique power person transform live patient society include individual country asia latin america eastern europe middle east africa e xcludes chugai workday lite company company use roche workday system lead hr system arm length alliance mergeracquisition agreementsenvironment know climate change large global challenge address matter urgency year team implement programme help reduce greenhouse gas ghg emission zero un sdgs material topic energy efficiency longterm mindsetthoma wolf chief environmental sustainability officer basel switzerland thomass love nature passion environmental protection lead career path thirty year later passion fuel work develop roche climate change mitigation strategyenvironment roche nerina itin environmental specialist rotkreuz switzerland nerinas work allow contribute development local environmental strategy engage colleague contribute individually site environmental goal thomas wolfenvironment roche steering sustainable energy future grow small town rural nahe valley issue climate change work west germany thomas wolf spend sustainable energy future year childhood outdoors explore nature area delay wait find meaningful home vast roll hill forest vineyard solution result dramatic backdrop disruptive expensive change future adventure young boy typical thomas explain proud roche childhood experience go school playing delay take action past sport friend spend spare way achieve goal time outdoors explains begin love nature passion implement carbon environmental protection dioxide reduction measure lead decrease carbon dioxide generate childhood passion outdoors operation world emission rise thomas credits chemistry teacher period goal achieve drive force interest science reduction engineering learning compare ask good career prospect area able achieve target attend university karlsruhe today continue ensure move karlsruhe institute technology graduate thomass answer simple clear degree chemical engineering thoughtout strategy enthusiastic long graduate thomass career engage team develop implement roche begin global engineering department plan happen vitamin division year later put passion take village good use role chief environmental order develop implement strategy sustainability officer m fortunate result meaningful change career help fight climate change collaborate internal external shaping roche climate change mitigation strategy stakeholder partner say thomas technical background definitely huge asset knowledge sharing impact effort work say thomas amplify network group function local site global energy summit sustainable energy future take place annually past year environmental goal ambitious reduce critical element foster close greenhouse gas ghg emission zero community subject matter expert share like company roche require energy passion meeting roche environmental goal operate order address energyrelate conscientious sustainable way site different consideration capability priority maintain open line communication collaboration way roche site world goal require diligent planning today work closely community imperative momentum continue especially site focus tangible result effort thing develop global strategy overarch target move duty contribute work site develop roadmap area long great sustainable energy future site community enthusiastic expert actively different consideration capability priority contribute support leadership maintain open line communication mark say collaboration way say thomas optimise vehicle fleet performance ask thing important site example optimise collectively difference thomas energy use manufacturing important swift clear answer mindful consumption feasible reduce consumption material resource like energy water future sustainable reuse recycling material thing accord thomas future positive impact entire value bright organisation work tirelessly chain experience dramatic past decade establish consequence climate change realise governance strategy environmental climate change big risk initiative stipulate guideline directive planet consequence fail mitigate set ambitious target implement monitor enormous social environmental mechanism team passionate financial system appreciate people dedicate make impact role play action help mitigate well future goal plan wish say generation come thomas meeting longterm zeroemissionenvironment roche thomass passion sustainability drive force year tenure roche help ensure climate mitigation strategy drive goal reduce greenhouse gas emission zero environmental protection challenge achievable complete bachelor degree clear measurable goal environmental engineer nerina technical measure itin classmate go pursue career working place engage employee nongovernmental organisation area reduce business flight like logical choice give difference environmental group active world nerina take different approach feel ambitious goal contribute company specific goal roadmap team environment main business rotkreuz develop ambitious impressed work roche stand particular reduction area environmental protection feel fossil fuel heat warm water zero knowledge skill good yes ambitious goal use easy decision apply definitely achievable explain nerina internship thrill offer able ensure role say nerina electricity come sustainable source reach high making impact past year nerina area focus site business flight making impact develop implement reduction promotion alternative form programme environmental specialist collaboration transportation diagnostic site rotkreuz switzerland employee site contribution site home central diagnostic customer clear impactful way help achieve goal area function include research nerina team drive add development production logistic nerina matter small say nerina work allow contribute s employee engagement important development local environmental strategy know impact roadmap engage rotkreuz contribute employee contribute individually site environmental goal collaborate site global safety security health environment protection person department team instrumental component nerina make difference site service lie work share knowledge good practice groundwork empower entire community learn challenge encourage action work new way try new thing main strategy implement sustainability goal incremental improvement nerina explain year yearenvironment roche nerina itin diagnostic site rotkreuz nerina help engage employee help achieve sustainability goal people working site contribution significant impact effort sustainable energy futureenvironment roche sustainability people genuinely care increase time people aware look future commitment come not hesitate consider future hold explain come environmental protection roche work area nerina hopeful mother environmental teacher grow greatly influence sustainability people genuinely interest area spend care increase childhood involve scout love time people aware nerina say nature outdoors destine think sustainable energy future absolutely begin possible matter roche achieve lot need nerina look forward challenging work go ahead study work roche far enjoy work field long future nerina follow feel contribute long passion continue study area possibly m constantly learn looking currently work master degree solution complex problem environment natural resource hope mindset behavioural change society develop knowledge bring meaningful change play role skill valuable work roche big small continue ask lifelong passion long future embrace environmental responsibility environmental protection intrinsic total environmental impact employee roche business approach decrease approximately sense responsibility methodically continue reduction greenhouse gas ghg approach issue concern quality productivity emission decrease waste costefficiency continuously monitor positive effect environmental impact environmental performance aim collect datum key performance indicator responsible approach energy usage ensure compliance high natural resource sustainable manner standard objective guarantee fundamental roche environmental strategy process equipment state art large proportion energy use come fossil fuel result produce ghg environmental risk mitigate system mainly carbon dioxide waste product prevention successful environmental risk contribute climate change air pollution management system company environmental minimising negative impact involve actively programme operational strategy cover contribute sustainable energy future climate change mitigation reduce emission include reduce energy consumption increase increase resource efficiency environmental efficiency implement innovative technology aspect procurement water waste increase use sustainable energy management complement strategy scope energy consumption set tangible quantitative mediumterm employee decrease reduction longterm goal achieve implement energysave measure reduce fuel use heat ecobalance cool operate site roche measure environmental impact ecobalance metric greenhouse gas emission climate change establish groupwide goal reduction environmental sustainability climate change level ecobalance refer mitigation hand hand critical consumption energy resource global issue understand business emission waste business activity challenge related climate change describe total environmental impact manage risk environmental operation allocate environmental impact risk management programme longterm point ecologically relevant parameter goal reduce ghg emission net zero consumption natural resource later validate new target emission air water soil obtain view science base target initiative sbti environmental pressure place significant ghg emission originate earth ecosystem point add transformation use energy relate total number employee energy reduction achievement enable monitor ecological impact parallel reduction scope employee ghg emission employeeenvironment roche water consumption noise pollution landfille waste energy consumption emission water roche emission air ecobalance vehicle operate electricity energy sustainable source company vehicle look way reduce energy consumption improve energy efficiency energy use aim renewable select type electricity business air travel video teleconferencing facility natural gas establish site widely employee encourage use train consolidate business trip scope scope market base capital good scope scope scope ghg emission ghg emission ghg emissions co co co purchase good scope scope service scope market base fuel energyrelate activity upstream transportation waste generate operation business travel use sell product direct emission operation indirect emission purchase energy emission result activity supply chain calculation methodology base ghg protocol follow hybrid activitybased approach approach refinement number comparable publish annual reportenvironment roche energy consumption terajoule total scope scope mark base energy scope scope mark base consumption gjemployee gj gigajoule halogenate hydrocarbon tonne inventory release global inventory include chugai genentech ventana include datum additional roche site wide scope halogenate hydrocarbon previous year emission air tonne voc particulate nitrogen oxides sulphur dioxide volatile organic compound water usage discharge water withdraw million water consume million organic matter discharge waterway treatment heavy metal discharge waterway treatment kg landfille incinerate waste tonne nonhazardous hazardous contaminate soil hazardous construction waste nonhazardous high remediation activity kesslergrube germany limited activity increase hazardous waste reallocation electronic waste hazardous waste environmental datum spark therapeutic flatiron health foundation medicine include roche environmental resultscommunity engagement tradition philanthropy exist roche century philanthropic effort unite common purpose lasting impact build strong healthy community global citizen support local effort un sdgs material topic longterm mindset availability healthcarelucia erniawati access communication health system value strategy lead jakarta indonesia role roche indonesia lucia see potential improve outcome patient live cancer help oncology nurse education gain recognition key partner patient carecommunity engagement roche margareth lasut oncology nurse north sulawesi indonesia margareth nurse enrol indonesia new oncology nurse specialist training programme look forward difference new expertise cancer patient lucia erniawaticommunity engagement roche bold vision big impact think new initiative make difficult develop specialist big question impact knowledge require provide effective society find answer care see opportunity real partner agree make find common longlaste impact ground easy nursing workforce challenge lucia erniawati chapter lead access imbalance distribution region mean communication health system value strategy region country underserve roche indonesia talk importance healthcare professional significant identify bold vision unite partner lack nurse specific oncology expertise different goal perspective lucia team see potential country like indonesia hugely special focus cancer care nursing decide complex health infrastructure need support catalyse launch specialise million people island span oncology training nurse indonesia time zone potential impact bold partnership significant partnership mean progress bold vision place team need ongoing project train specialist oncology gain buyin stakeholder include nurse example indonesian ministry health indonesia university dharmais national cancer center cancer survival rate indonesia significantly oncology nursing association lower develop country low awareness poor diagnostic capability partner perspective lack specialised care facility explore goal agree potential benefit pain point patient continuum training oncology nurse significant care lucia team realise scale begin work implement plan problem compound absence core scholarship programme support specialised nurse provide care patient roche corporate donation philanthropy cancer emerge market scholarship programme train oncology nurse indonesia university help oncology nurse play important role develop countryspecific cancer care help patient entire journey research suggest majority progress significant nurse learn deal complexity cancer basic oncology nursing training curriculum treatment palliative care job say accredited ministry health programme addition compete healthcare priority trainers certify nurse certify rotate position basic oncology nursing training student s corporate donation philanthropy work good standalone grant starting point catalyst real meaningful change enrol threeyear oncology nurse programme support specialist training programme global corporate donation philanthropy team ultimately goal donation future goal include place oncology nurse partnership collaboration specialist archipelago selfsustaine core value province open new training centre come roche philanthropic initiative establish oncology nurse specialist programme university establish centre excellence momentum start build worst affect area stunt country serve proof concept significance initiative partner region say regional fully invest vision oncology nurse government quickly commit adopt longterm solution spread project area clearly word project grow benefit programme take life say lucia able act instigator catalyst standalone grant starting point ongoing partner establish centre catalyst real meaningful change link key policymaker potential partner access care personal passion grow country centre year roche lucia proud ensure ongoing longterm sustainability involve catalyst change indonesia include effort lucia passion impact extend rebuild healthcare centre large fundraising activity include cook earthquake programme reduce raise fund annual roche children percentage child affect childhood walk company large employeedriven stunt significant issue indonesia philanthropic event low lowermiddleincome country lucia highlight work home want programme great example difference say likeminded people project quickly build momentum come achieve amazing thingscommunity engagement roche lucia passionate unite partner meaningful goal help establish oncology nursing scholarship indonesia helping set centre excellence reduce childhood stunt lucia know collaborate truly difference bring specialised oncology nursing home margareth lasut literally bear journey begin medical profession childhood margareth apply programme indonesia north sulawesi province saw quickly accept fellow scholarship mother dedicate nurse difference recipient travel country live countless patient young jakarta begin study september girl margareth know want follow footstep programme interactive interesting say limit express not know early day learn impact people large important impact possible continually work improve community knowledge skill see need seek solution new concept margareth margareth registered nurse study cite care continuum quickly realise want help interesting helpful ve learn patient access high level care cancer nurse not treat patient aware care cancer patient north ve arrive hospital diagnosis sulawesi need improvement hospital explain start margareth work large region cancer treatment begin prevention early stage develop cancer unit detection provide specialised care way rehabilitation stage endoflife early margareth supervisor tell experience outcome firstofitskind programme provide scholarship specialise oncology nursing aspect love programme learn programme opportunity visit hospital develop university indonesia jakarta eye advance support roche accept application cancer care look like margareth immediately know find way improve care home say improve quality care people community bring benefit home margareth return north sulawesi programme answer prayer training complete margareth explain give opportunity oncology nursing specialist province expand nursing knowledge population million people good educational institution indonesia look forward difference bring knowledge colleague new expertise cancer patient ultimately help patient family explain year number cancer entire community patient region increase hope becommunity engagement roche margareth lasut student enrol oncology nurse specialist training programme margareth know play role help educate nurse care living cancer believe education key component help alleviate overburden healthcare system indonesiacommunity engagement roche think patient learn realise learn able access believe scholarship programme combine quality care understand benefit oncology nursing specialist provide lead want share new knowledge continue increase nursing specialist hospital nurse encourage continue indonesia ask hope education cancer treatment future margareth say think hope north sulawesi continue improve far use knowledge change people live future margareth look forward complete increase number oncology nursing study return home husband specialist indonesia hopefully family spend quiet evening home help alleviate overburdened state healthcare ask surprised working system margareth explain know cancer patient reply thought add oncology nursing specialist patient learn realise hospital staff low overall cost treat learn cancer patient nurse help educate ve teach importance family colleague turn increase access show maintain hope care patient difficult time focus community impact philanthropy catalyst year ahead support wide range meaningful sustainable change mindset scholarship emerge market table core philanthropic strategy opening path new possibility organise key pillar humanitarian education new nurse health support community project education worker lab technician programme cultural collaboration bolster employee engagement multistakeholder approach trust believe longterm sustainability partner ground philanthropic societal change rely engagement ambition reality way ensure local community mantra extend project initiative support meet employee fact large employee quality innovation sustainability criterion engagement philanthropic event begin employeedriven pilot contribute healthy community site roche children walk philanthropic initiative help build site participate campaign strong healthy community live country garner support work example employee support support international committee local project global project red cross icrc year roche employee action charity trust longeststande partnership span nearly react long found company continue evolve major focus year group engage recent year helping improve access employee world select water mali lack access vital children walk ambassador witness resource acute protract conflict impact employee fundraising activity firsthand drought limited resource follow threeyear pause covid people benefit initiative pandemic ambassador visit react project help bolster community access basic primary healthcare service include child dream cambodia support transnet phelophepa healthcare foundation dedicate improve children train provide service education support help build evolve meet press health need school outfit computer lab provide rural community south africa scholarships selam childrens village phelophepa provide healthcare service ethiopia support orphan patient train community home child difficult healthcare volunteer food garden start life mother mother malawi enable food security region support help improve health wellbee adolescent girl hivpositive well example sustainable hivexpose unicef malawi change provide people train help girl school need build healthy community menstrual health hygiene campaigncommunity engagement roche philanthropic contribution roche group world corporate donation philanthropy cdp fondation roche recherche en afrique frra roche employee action charity trust react local philanthropic project global emerge market scholarship programme cdp corporate donation philantropy frra fopnhildanathtrioopicn roche recherche en afrique country recipient organisation discipline scholar react roche employee action charity trust cambodia child dream react high school local philantrophy universit atlantique frra lab technician unit de formation et de recherche cte divoire science mdicale dabidjan frra pathologist ethiopia selam react vocational ao alliance frra trauma orthopaedic ghana college nurse midwive frra oncology nursing ghana eth zrich foundation frra mechatronics engineer india kiran cdp university indonesia universitas indonesia cdp oncology nursing amref frra community health worker kenya zero cdp nursing christel house cdp middle school south africa maharishi institute cdp business peru colombia el salvador guatemala fundacin educacin cdp business total patient receive healthcare service phelophepa south africa people benefit icrcs access water initiative mali employee support roche children walk illustrative map recipient country exhaustivebusiness ethic believe integrity basis sustainable successful business employee responsibility behave integrity accordance share value compliance guideline expect partner work meet integrity standard un sdgs material topic human right ethic transparency patient centricity availability healthcare complianceli bao regional sale lead beijing china li know critical diagnostic accessible people place responsibility late development diagnostic technology regulation govern thembusiness ethic roche matteo alaria head product sustainability sartorius torino italy matteo responsible drive sartoriuss sustainability effort ensure client like roche look opportunity reduce resource energy use implement sustainable solution li baobusiness ethic roche transform business model well serve patient role regional sale lead roche arrangement roche responsible diagnostic china li bao know keep ensure instrument work advancement diagnostic order repair replace machine instrument process ongoing task need return reagent portion understand importance expand contract provide company access advancement people predictable source revenue time possible s work hard stay current industrystandard model support grow late development diagnostic technology healthcare industry necessary ensure available people place healthcare market particularly diagnostic sector undergo rapid growth task connect people roche china chinese government begin question diagnostic tool entail keep particular model actually change regulation govern good patient national medical impend regulatory change china products administration nmpa determine necessitate complete transformation way separate financial arrangement large portion company business li know diagnostic instrument financial entire team face particularly difficult test arrangement reagent increase agility allow hospital quickly adopt new instrument year experience roche diagnostic technologie well experience responsibility core line business li patient new regulation effect comfortable professional challenge begin transition period regulatory change major transformation year critical business process room error li team quickly see understanding challenge likely demand journey regulatory change necessary thing right simple surface actually the substantial modification way roche competitor business li team shift need grow market task ensure compliance regulatory change hospital new regulation smooth possible healthcare facility typically lease diagnostic instrument agreement reaction roche facility commit purchase specific large industry confusion explain li reagent substance conduct understand rationale gain clarity diagnostic test produce result order roche team begin talk regulator ask instrument provide period question work develop clear idea contract require make change investment country commitment provide access quality healthcare people benefit patient include increase instrument review thousand exist transparency access new technology contract find potential issue problem soon apparent impact roche begin develop solution new evident li see arrangement customer roche offer highquality instrument align new regulation reagent exceptional level service new business model unlikely negatively long journey say li able impact operation explain complete transition come make change year speak honestly investment country difficult great deal commitment provide access quality work involve healthcare people transparently comply local regulation keep compliance centre conduct business ethically compliance task happen regulation especially change core principle roche li elaborates gather team value roche place compliance way li immediately sure path monthly meeting compliance know focused compliance day truly crossfunctional undertaking compliance day s update team assemble develop strategy compliance news discuss challenge transformation include representative face determine need finance legal compliance sale ensure need department group begin connect external stakeholder include hospital ready s device distributor determine well massive undertaking nearly complete way transition new regulation li likely sit long lifelong minimising disruption commitment stay healthy active involve swim jog basketball badminton large portion work fall sale son follow footstep show team work closely customer great promise swim family hospital lab inventory current wide commitment keep pace lifebusiness ethic roche healthcare system china evolve li colleague ensure roche continue provide access quality healthcare people work partner healthcare system ensure compliance new regulation minimise disruption patient healthcare provider demonstrate value sustainability sartorius global supplier innovative constantly push technology service enable roche supplier find opportunity biotechnology company simplify reduce resource energy use accelerate progress biomanufacturing matteo look sustainable solution aspect alaria sartoriuss head product sustainability business say matteo end life breathe sustainability environmental day benefit approach engineer training combine client supplier environment passion career love ultimately patient environment thirst thing datarelate value collaboration job consultant working biomanufacturing industry extremely complex variety industry join sartorius fast progress benefit rewarding experience help company patient increase organisation think act sustainably reflect collaboration simplification matteo climate change big opportunity speed sustainability challenge face society today effort industry need ask act change future question like well new innovation singleuse technology fast access patient explore package sustainability sartoriuss corporate product efficiently value openness enjoyment company take holistic view find resource matteo believe roche leader efficient innovative technology solution biotechnology industry great opportunity help client translate new scientific pave way come industry discovery quickly effective patient collaboration open dialogue supplier care progressing sustainability partner find common ground goal sartorius look entire value chain industry embe sustainability research development manufacturing board roche datadriven company storage transportation medicine say way connect sustainability vaccine speed time take business find solution datum patient benefit matteo role exactly roche operate business ensure happen sustainability mindset critical future industry core ethical responsibility grateful collaborate roche support access innovative medicine make meaningful change people sustainable way possible matteo saysbusiness ethic roche matteo alaria matteos lifelong passion sustainability propel explore new innovative way help client reduce resource energy use believe company like roche lead way biotechnology industry help set standard company sustainable futurebusiness ethic roche way connect sustainability business find solution datum exactly roche operate business knowledge power sartorius take approach matteo team sartorius know indepth function prior pandemic knowledge client process operation appreciative worklife balance integral provide need role allow spend time family job learn client collaborate colleague client operate identify right solution world reflect matteo mention good possible performance say fact truly sustainable approach matteo degree view help work capture opportunity improve sustainability value chain consider future hold matteo speak threemonthold daughter live value future s important s drive sartorius headquarter gttingen difference way look germany matteo work home office forward continue work client torino italy grow covid demonstrate value pandemic speed remote working approach sustainability heart embed ethic integrity compliance organisation centralise monitoring maintain strong ethical culture system able free capacity remain main focus comprehensive compliance professional well support compliance programme business complex matter focus digitalisation simplification compliance process control ensured develop business partner management compliance expert involve early checklist provide harmonised approach new business model management external business partner promote integrity standard globally initiative conclude successfully implement lead early human right involvement compliance officer roche respect proactively protect human driving line management ownership right leverage current human right culture integrity compliance time programme move holistic transformation approach value chain include external supplier human right programme harmonise compliance risk opportunity crossfunctional team develop assessment management framework directive human right diligence roll framework allow focus party update roche supplier code relevant big risk conduct golive date january opportunity identify potential gap initiative increase transparency trend enhance human right programme roche operation new business ethic incident management system beim successfully implement way ensure compliance allow capture key datum order supplier code conduct well understand root cause noncompliant supplier sustainability assurance visit ssav behaviour trend act programme formal riskbase method identify supplier risk effort drive awareness engagement sustainabilityrelate violation include organisation revise launch human right violation supplier simplify version behaviour business subject recur audits ssav directive simple language easy programme conduct ssavs navigation ensure employee emea apac north america clear understand key topic include latam human rightsrelate conflict interest corruption observation audit supplier commit document corrective action plan address begin implement improve audit finding followup audits conduct standardised process interaction verify corrective action take healthcare professional healthcare adequately address root causesbusiness ethic roche active pharmaceutical ingredient chemical contract research organisation laboratory supply logistics transportation human rightsrelate finding industry waste management clean telecommunication temporary labour common critical major finding category excessive overtime incorrect overtime compensation grant number day annual leave delay payment wage compliance employee roche group speakup line operate external provider available language countrie chief compliance officer receive report allege violation code conduct business ethic incident management system unfounded found investigation result employment contract agreement business partner terminate ground unethical behaviour compare year high number report allege violation broaden scope definition business ethic incident removal materiality criterion march corporate governance roche corporate governance corporate governance principle focus business activity sustainable value creation innovation prescribe management culture conforming recognise standard good corporate governance policy transparent communication material topic compliance principle business activity focus sustainable relevant corporate governance requirement value creation innovation management particular applicable law swiss stock culture conforming recognise standard exchange swiss exchange directive good corporate governance policy swiss code good practice corporate transparent communication embody roche governance promulgate swiss business corporate governance principle build federation economiesuisse company internal basis successful implementation roche governance framework particularly article commitment serve stakeholder incorporation bylaw embody principle need ensure company strong board director represent business manage supervised interest shareholder manner consistent good corporate governance stakeholder highly skilled manager include necessary check balance act integrity extremely important print annual report contain select link roche rank roche website httpswwwrochecom sustainable healthcare company reader provide snapshot pharmaceutical index dow jones company report date sustainability index djsi th year direct source consult run recognition base indepth time uptodate information corporate analysis economic social environmental governance roche annual report performance sustainability core cover single financial year end december business practice award reflect website contain information commitment run business way permanent nature late roche news ethical responsible create longterm company article incorporation bylaw value stakeholder curricula vitae current member board director corporate executive corporate governance report set committee publish website status structure process rule roche end term reporting date take basis wellfunctione corporate december year governance roche complie year httpswwwrochecomaboutgovernancecorporate governance roche annual general meeting annual general meeting board director board director board committees board committee chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pred pharma partner communication general counsel board director review agm review report year accordance art federal act announce july roche chairman statutory principle federal council dr christoph franz decide stand ordinance combat covid epidemic reelection member chairman covid act art ordinance board director agm march measure combat coronavirus covid dr franz elect roche board covid ordinance th annual general director serve chairman meeting agm roche holding ltd hold march shareholder attend person shareholder request september julie brown step exercise right independent proxy member roche board directors testaris ag address question immediate effect accept company write management role pharmaceutical company julie brown elected board agm roche holding ltd march director march subsequently shareholder reelect dr christoph franz chair audit committee dr patrick frost chairman board director term take chairman audit committee year provide article incorporation interim basis agm roche holding ltd furthermore agm reelect andr hoffmann julie brown dr jrg duschmal dr patrick frost outlook agm anita hauser prof dr richard p lifton bernard march forthcome agm poussot dr severin schwan dr claudia board director nominate dr severin schwan suessmuth dyckerhoff member board new chairman election dr schwan director term year provide serve member roche board director article incorporation time dr schwan resign member corporate executive committee dr jemilah mahmood elect new member ceo roche group board director term year addition agm elect dr christoph franz board directors nominate andr hoffmann prof dr richard p lifton remain member board director bernard poussot dr patrick frost member reelection recommend follow new remuneration committee term year member election board director agm prof dr akiko iwasaki sterling organising meeting immediately follow professor immunobiology molecular agm board director determine cellular developmental biology yale structure composition remain university investigator howard committee show hughes medical institute dr mark schneider board director chief executive officer nestl corporate executive committeecorporate governance roche board director nominate board directors dr annette luther dr jrg duschmal anita hauser new appoint head international government andr hoffmann prof dr richard p lifton relation april bernard poussot current member election remuneration committee agm board directors nominate testaris ag election independent proxy agm perolof attinger currently head ceo period conclusion office secretary corporate executive ordinary agm shareholder committee secretary board director board committees board director chairmansnomination committee board committees remuneration committee corporate governance sustainability committee audit committee board director member nationality malaysia france austria female switzerland male germany year year year year year year age tenure average tenure incl ceo year excl ceo incl dual citizen triple citizen calculate year election corporate governance roche composition year birth elect board director dr christoph franz c e g chairman andr hoffmann c e g vicechairman representative shareholder group pool voting right dr jrg duschmal b e g representative shareholder group pool voting right dr patrick frost b c e g anita hauser e g prof dr richard p lifton c e g dr jemilah mahmood e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g secretary dr annette luther board directors curricula vitae cvs member board director current member httpswwwrochecomaboutgovernanceboardofdirector b member year httpswwwrochecomaboutgovernanceecbodformer c information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvs corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson board directors b c committees andr hoffmann chair dr patrick frost chair andr hoffmann chair dr christoph franz chair anita hauser dr jrg duschmal dr christoph franz andr hoffmann dr jemilah mahmood dr claudia suessmuth dyckerhoff dr patrick frost dr claudia suessmuth dyckerhoff prof dr richard p lifton bernard poussot corporate executive committee membership corporate executive work different country committee remain unchanged leadership function ceo diagnostic division member william pao head roche pharma research corporate executive committee august early development pred member enlarge corporate executive committee leave announce october effective roche march new opportunity january matt sause head united states roche diagnostic north america region ceo roche diagnostic member prof dr hans clevers join board corporate executive committee matt sause begin director step position career roche indianapoli united states appoint new head roche pre progress numerous leadership effective march member role multiple country include japan taiwan enlarge corporate executive committee ireland peru south korea join report directly roche group ceo genentech assume role regional head roche diagnostic north america announce july board director hold bachelor degree microbiology decide propose roches group ceo dr severin schwan new chairman agm bill anderson ceo roche pharmaceutical march time dr schwan member corporate executive committee resign member corporate executive decide pursue opportunity outside roche committee ceo roche effective december dr thomas schinecker group ad interim ceo roche pharmaceutical start january effective march board director appoint dr thomas schinecker currently information member corporate ceo diagnostic division dr schwans executive committee enlarge corporate successor ceo roche group dr schinecker executive committee list grow asia earn phd molecular board director biology united states join roche corporate executive committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceutical diagnostic information officer officer enlarge corporate executive enlarge corporate executive committee committee gre pred pharma partner communication general counselcorporate governance roche composition year birth position corporate executive committee dr severin schwan ceo roche group bill anderson ceo roche pharmaceutical dr thomas schinecker ceo roche diagnostic dr alan hippe chief financial information officer cristina wilbur chief people officer enlarge corporate dr aviv regev head genentech research executive committee early development gre prof dr hans clever head roche pharma research early development pre dr james h sabry global head pharma partner barbara schdler head group communications claudia bckstiegel general counsel secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey mark baillache franois rouiller chief compliance officer pascale schmidt curricula vitae cvs member corporate executive committee enlarge corporate executive committee current member httpswwwrochecomaboutgovernanceexecutivecommittee b member year httpswwwrochecomaboutgovernanceecbodformer c information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvs group structure shareholder roche operate business organise information roche holding ltd significant division pharmaceutical diagnostic subsidiary associate company include company list information domicile share pharmaceutical division comprise capital equity interest list finance business segment roche pharmaceutical report note roche group consolidate include genentech united states financial statement list subsidiary chugai associate diagnostic division replace major shareholder list finance previous business area structure report note roche group business area new customer area sale consolidated financial statement equity present follow customer area attributable roche shareholder relate core lab molecular lab point care pathology party page note lab diabetes care detail finance report financial statement roche holding ltd significant shareholder addition significant shareholder publish business activity carry group relevant webpage link subsidiary associate company detail disclosure office exchange regulation roche pharmaceutical incl genentech pharmaceutical chugai core lab molecular lab diagnostic point care pathology lab diabete care composition exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtmlcorporate governance roche andr hoffmann chairman corporate governance sustainability committee remuneration committee dr jrg duschmal member audit committee andr hoffmann vicechairman board directors chairman remuneration committee board corporate governance sustainability committee member board chairmansnomination committee dr jrg duschmal member board director boards audit committee serve respective capacity board committee representative shareholder group pool voting right receive remuneration set forth remuneration report finance report note roche group consolidate financial statement relate party relationship exist shareholder pool voting right crossshareholding capital structure information roche capital structure provide earning liquidation proceed follow finance report note financial repayment share capital roche ne statement roche holding ltd right pertain thereto include provision additional detail contain article protect interest ne holder incorporation roche holding ltd describe article incorporation roche holding ltd movement recognise amount financial year detailed finance information debt instrument report note financial statement issue outstanding bond provide roche holding ltd finance report note roche group consolidate financial statement debt extraordinary general meeting hold november shareholders agree information employee stock option provide reduce company share capital finance report note roche chf chf group consolidated financial statement equity cancellation share compensation plan include detailed repurchase company novartis information stocksettle stock appreciation holding ag pursuant repurchase agreement right ssar plan restrict stock unit date november share capital rsus plan roche connect roche divide fully pay bearer share option plan nominal value chf restriction exercise voting right roche issue option apart employee bearer share stock option describe finance report note roche group consolidated authorise conditional capital financial statement equity compensation plan option issue connection addition nonvoting equity debt instrument security nes issue bearer form form share capital option award employee confer voting right ne confer debt instrument issue right share participate available effect roche share capital httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche board director corporate executive committee information member board director independence definition base director member corporate definition swiss code good practice executive committee list page corporate governance economiesuisse member board director age limit complement specific precede criterion restriction term office httpswwwrochecomaboutgovernance boardofdirectors curricula vitae cvs current member year body principle governance principle information include information delegation competence reservation power year election board membership management group company additional position membership activity executive body company include available continuously update internet economic environmental social topic addition status cvs body principle internal organisation relevant reporting date december board director division authority year separately available responsibility board management remit board committee rule pursuant article para point vegv information control mechanism number permit activity board available board dealing corporate director corporate executive committee management govern bylaw member outline article incorporation roche holding ltd board director roche holding ltd organise ensure group conduct annual general meeting elect business responsibly focus member board director chairman longterm value creation end roche board director members board delegate certain responsibility remuneration committee annual basis committee composition election nominee vote chairperson december describe separately article incorporation page committee authority roche holding ltd minute responsibility define detail th ordinary annual general meeting roche bylaw board director hold ltd hold march committee chair independent exception dr severin schwan director member board director office end member roche accord bylaw board director corporate executive committee serve board meeting convene executive capacity group subsidiary chairman present request financial year precede current member roche board meet year report period lack exist assess chairman performance meeting business connection group attend chairman chair group subsidiary independent roches board vicechairman httpswwwrochecomaboutgovernanceboardofdirector httpswwwrochecomaboutgovernanceexecutivecommittee httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernanceannualgeneralmeeting httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancecommittee httpswwwrochecomaboutgovernancearticleofincorporation board director board director board committees board committee chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceutical diagnostic information officer officer management information dialogue consolidate group risk report system mis board access include target risk profile discuss electronic information platform provide corporate executive committee approve timely information board director group business plan material board committee system risk review board yearly basis control set forth effectiveness risk management process monitor group risk advisory team board director establish system overall process regularly review control continuously monitor external auditor finding present audit committee corporate governance audit committee board detail sustainability committee board risk management risk management policy director consist follow element risk management website financial report operate financial risk risk risk management specifically describe management system finance report roche group establish risk system internal control financial reporting management process cover entire company finance report system place identify manage internal audit type risk opportunity potentially group audit report administrativelyto general affect business include economic counsel direct access give regular environmental social impact board briefing audit committee corporate director high governance body involve governance sustainability committee roche risk management policy set chairman board director approach accompany responsibility ongoing activity audit report chief roche pharmaceutical diagnostic audit risk advisory executive attend audit division global function conduct formal committee partly corporate governance assessment process year sustainability committee meeting develop risk plan material external auditor group audit independent risk opportunity monitor appraisal function evaluate review deviation review regular performance group activities service board httpswwwrochecomaboutsustainabilityapproachriskmanagement additional information provide finance report note roche group consolidate financial statement risk management corporate governance roche director management annual follow blackout period arewere effect audit plan yearly define focus area eg respectively commercial activity distributor management healthcare compliance validate senior blackout period management approve audit committee roche group commit december december maintain high standard internal control february february worldwide operation management april april april april responsible assess business risk june july june july aspect operation implement october october effective efficient process control october october whilst ensure compliance internal external rule regulation conduct operational audits group audit determine blackout period change chairman management response risk surround board director circumstance warrant business process system evaluate appropriateness completeness efficiency roche employee involve preparation process control action plan regular publicity event particular annual implement necessary change enhancement halfyear report medium conference develop businessauditee quarterly sale release track completion access potentially share price sensitive statutory auditor information roche subject black chief compliance officer compliance period irrespective relevant officer subsidiary information share price sensitive roche safety security health environmental blackout period person protection department shall relevant information confidential corporate sustainability steering committee disclose noninsider science ethic advisory group seag outside roche include family member ii buy sell trade equity security member corporate executive committee roche share nonvoting equity security invite attend meeting board nes option similar instrument director report person derivative base thereon iii provide agenda item concern situation trading recommendation thereon automatic warrant member enlarge corporate execution predefine periodic purchase order executive committee invite attend roche connect programme board committee invite chairman subject blackout periods board corporate executive committee member deliver report committee meeting addressee scope exception elect commission independent expert regard blackout period refer report service consultant roche group insider directive httpsasset cwprochecomfxebgroup year blackout period impose insiderpolicypdf member board director senior manager certain employee prohibit trade company stock httpswwwrochecomaboutsustainabilityenvironment httpswwwrochecomaboutsustainability httpswwwrochecominnovationethicalstandardsadvisory dr patrick frost chairman audit committee board director meet meeting meeting hour length include fullday meeting addition board go day trip european affiliate board committee meet follow chairmansnomination committee meeting approx hour remuneration committee meeting approx hour audit committee meeting approx hour corporate governance sustainability committee meeting approx hour board director regularly conduct assessment selfassessment assessment party electronic survey personal interview performance assessment party board assessment perform designate new chairman board director conduct personal interview member board director member corporate executive committee maximum ordinary notice period month changeofcontrol clause employment contract management contract fall scope subsection annex directive information relate corporate governance remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activitiescorporate governance roche attendance board board committee meeting corporate governance chairman nomination remuneration audit sustainability board committee committee committee committee number meeting c franz hoffmann j duschmal p frost hauser r p lifton j mahmood member board march b poussot schwan c suessmuth dyckerhoff p bulcke member board march h clevers member board march j brown member board september member committee member march member march member september remuneration shareholding loan detail remuneration shareholding rule aoi loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional page finance report payment member note roche group consolidated executive committee financial statement equity attributable roche appoint vote shareholder relate party page pay annual general list note financial meeting shareholder statement roche holding ltd board rule loan credit facility executive shareholding postemployment benefit rule vote pay follow rule remuneration shareholding agm loan board director board corporate executive committee cec set forth article incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche participatory right shareholder participatory right shareholder article incorporation define roche article incorporation shareholder represent share nominal roche share issue bearer value chf million request restriction admission annual general placement item agenda annual meeting exception share general meeting later deposit specify period day date meeting date meeting admittance card issue shareholder provide rule issue instruction article incorporation shareholder independent proxy rule electronic elect represent party participation annual general meeting annual general meeting lay correspond invitation annual general meeting regulate article incorporation contain restriction article incorporation exercise voting right quorum requirement stipulate conformity swiss code obligation change control defensive measure article incorporation contain provision nonvoting equity security terminate mandatory bid rule swiss law apply event acquisition vest period restriction preexist award changeofcontrol clause remove option component remuneration base roche exercise immediately httpswwwrochecomaboutgovernancearticleofincorporation relationship statutory auditor annual general meeting roche holding ltd auditor direct access audit march shareholder vote committee chair head appoint kpmg ag kpmg statutory auditor group audit discuss relevant issue base exist legal requirement swiss report statutory auditor code obligation article concern consolidated financial statement maximum term office seven year auditor financial statement find page charge franois rouiller auditor respectively finance report charge business year information long auditor charge serve kpmg receive follow remuneration capacity provide service statutory auditor roche holding ltd auditor roche company statutory auditor participate audit include chugai committee meeting prepare write oral report result audits audit committee oversee assess auditor millions chf make recommendation board auditing service information authority responsibilitie auditrelated service audit committee article assurance bylaw statutory auditor participate nonstatutory audit meeting audit committee tax service service performance kpmg assess base total different element affiliate survey evaluate service level country level interview roche key stakeholder audit fee review head group audit selfevaluation kpmg internal process approve audit committee year ensure compliance federal audit oversight take consideration change roche authority faoa audit committee guide business change financial reporting audit standard regulation kpmgs independence ensure limit kpmg provide certain nonaudit services statutory auditor elect year furthermore permit service exceed annual general meeting total audit fee explicitly rewieve approve audit committee auditing service provide legally require company formal policy governing engagement statutory auditor nonaudit auditrelated service include assurance service limit certain permit accounting service provide auditor service agree audit committee necessarily provide statutory potential nonaudit service engagement auditor service legal review policy authority requirement include attestation procee give service comfort letter consultation httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche tax service include service respect rfi culminate shortlist audit compliance tax return tax advice firm invite request proposal service relate audit tax rfp phase rfp phase complete service include advice relate process phase audit tender conduct improvement regulation training involvement key stakeholder thorough independent process line external audit service tender predefine evaluation criterion audit firm initiative roche audit committee provide appropriate access roche management audit firm invite participate relevant financial nonfinancial tender external auditing service start information relevant respective proposal financial year base assessment audit firm project team manage tender process tender process board director phase request information rfi phase propose shareholders reappoint kpmg conduct course external auditor financial year relationship independent proxy testaris ag serve general meeting period independent proxy annual general conclusion ordinary annual meeting march shareholder elect general meeting shareholders testaris ag independent proxy period conclusion ordinary rule issue instruction annual general meeting shareholders testaris ag independent proxy rule electronic pay service annual general participation annual general meeting meeting accord expenditure totalling lay correspond invitation chf chf ordinary annual general meeting regulate extraordinary annual general meeting article incorporation board director nominate testaris ag election independent proxy annual information policy provide article incorporation presentation analyst investor conference corporate notice publish swiss available internet publication official gazette commerce daily available newspaper designate board director httpswwwrochecompublications basler zeitung finanz und wirtschaft lagefi order email le temps neue zrcher zeitung materialsmanagementmmrochecom fax roche report halfyear fullyear result business report publish print andor online contact address investor relation format medium event addition detail f hoffmannla roche ltd investor relation firstquarter month sale figure group finance basel switzerland publish year april october tel current list publication date available fax internet additional information include detail relevant information document include specific contact person available medium release investor update internet httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecommedia httpswwwrochecominvestor httpswwwrochecomcontactinvestorcontactscorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance reach line manager local officer network commit ensure compliance officer chief compliance officer roche group code conduct consistently contact roche group code conduct comply roche group help advice line compliance tool serve chief compliance officer serve contact platform idea suggestion concern person shareholder employee business document partner customer supplier general public issue relate implementation addition roche establish business compliance code ethic incident management system beim enable line management compliance employee party aware officer chief compliance officer violation roche group code conduct capture track monitor allege violation bring attention manager initial report resolution supervisor local compliance officer report chief compliance officer business ethic incident record ms pascale schmidt system internal investigation team email pascaleschmidtrochecom regionallocal management receive specific tel disclosure concrete information allege violation treat confidentially addition employee roche group code conduct party anonymously report irregularity certain predefine category corporate complaint mother tongue roche governance sustainability committee group speakup line continuous audit committee board director enhancement roche human right programme regularly inform substantial violation compliance applicable law management corrective action take regulation interested party report allegation channel believe chief compliance officer report good faith actual potential human right general counsel submit regular report violation occur roche roche value corporate governance sustainability chain case question uncertainty committee need audit committee interpretation roche group code board director conduct reference document employee nonapplicabilitynegative disclosure expressly note information negative declaration provide contain mention swiss exchange corporate governance nonapplicable omission construe directive commentary thereto httpswwwrochecomaboutgovernancecodeofconduct httpswwwrochecomaboutgovernancecodeofconductcomplianceofficer httpswwwrochecomaboutgovernancecodeofconductremuneration report roche remuneration report employee compensate fairly transparently competitively participate appropriately company success optimal condition enable employee good possible contribution improve healthcare patient principle motivation expertise performance transparent compensation structure ensure employee key success roche compensation package competitive innovative agile company conviction structure individual component form basis compensation policy regularly benchmarke base relevant swiss european international market criterion roche aim remunerate employee fairly remuneration guideline underlie transparently line market condition principle subject regular outside enable participate appropriately comparison company success pursue goal provide equitable competitive performance compensation policy base resultsoriente compensation factor safeguard roche future success key element corporate culture strive balanced mix fix variable offer employee condition compensation component gear good possible contribution employee position management responsibility share corporate goal improve healthcare patient include sound firstly variable component intend sustainabilityoriente value system create additional financial incentive achieve base integrity courage passion corporate goal innovation time decentralise management consistently high level increase value approach play major role wide scope company create stakeholder individual decisionmake respectful group secondly order allow employee interaction openness diversity wideranging manager participate company train development opportunity business success adequate compensation attractive working environment unidimensional measure key objective incentivise diminishment question remuneration annual bonus payment longterm fall far short securitiesbase programme roche commit fair performancebase global company like roche market resultsoriente compensation policy competitive remuneration play key role link employee interest performance successbase stakeholder group roche place work httpscareersrochecomglobalenremuneration report roche remuneration decision process approval framework overview present remuneration committee year remuneration committee roche decide correspond compensation board director decide remuneration right decision decision board member member group right reserve remuneration committee corporate executive committee member chairman group ceo member group corporate executive committee remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman c committee cec incl ceo roche group base pay remuneration bonus c stocksettle stock remuneration committee annual general meeting appreciation right ssar restrict stock unit rsus pension c remuneration committee track market datum total aggregate amount salary lead global pharmaceutical base decision submit company major swiss company general meeting approval implement report finding board external ordinance excessive compensation consulting firm pricewaterhousecoopers ag pwc list jointstock company verordnung gegen assist remuneration committee roche bermssige vergtungen bei brsenkotierten perform market comparison advise aktiengesellschaften vegv general meeting pwc award additional mandate shall vote annually bind effect roche group information remuneration approval remuneration board committee remit power procedure director resolve board director make remuneration decision find corporate executive committee detail bylaw roche board director article incorporation outline section principle govern specific remuneration component peer set abbott laboratories abbvie amgen astrazeneca bristolmyers squibb danaher eli lilly glaxosmithkline johnson johnson medtronic merck co novartis novo nordisk pfizer sanofi peer set abb alcon credit suisse holcim lonza nestl richemont ubs zurich httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancearticleofincorporation abbott laboratories peer set abbvie amgen abb astrazeneca alcon bristolmyers squibb credit suisse danaher holcim eli lilly lonza glaxosmithkline nestl johnson johnson roche richemont medtronic ubs merck co zurich novartis novo nordisk pfizer sanofi peer set market comparison company salary assessment pharma peer set major swiss company procedure submit total board retrospective approval executive remuneration shareholder total aggregate bonus amount corporate approval annual general meeting executive committee chairman year annual general meeting agm board director financial year end shareholder approve total remuneration submit retrospectively ordinary board director corporate agm separate bind approval executive committee decide board director remuneration committee prospective approval board director respectively board executive aggregate remuneration submit prospectively accord approval agm agm separate bind approval roche commit obtain separate period ordinary agm bind shareholder approval total remuneration pay board director remuneration report shall submit corporate executive committee follow advisory vote shareholder agm remuneration report roche andr hoffmann chairman remuneration committee approval total remuneration annual general meeting agm financial year financial year approval total remuneration retrospective c bonus chairman c board director bod bonus financial year total cec corporate executive committee cec include ceo roche group bonus bonus financial year total prospective bod base pay remuneration board director bod include chairman c aggregate total remuneration agm agm base pay remuneration cec corporate executive committee cec include ceo roche group base pay aggregate total remuneration agm agm ssar base pay rsus stocksettle stock appreciation right ssar indirect benefit restrict stock unit rsus indirect benefit advisory vote retrospective remuneration report advisory vote remuneration report agm agm agm agm remuneration component overview remuneration element performance nonfinancial success remuneration member board align interest roche employee director corporate executive committee shareholder societal environmental compose follow element objective take account fix base salary complement lti remuneration component intend annual variable bonus shortterm incentive sustainably homogenously longterm sti perennial remuneration element orient perspective align management interest ssar rsus longterm incentive lti shareholders holder non vote equity security participate remuneration component link manager additional incentive achieve employee performance company financial sustainable shareholder value growth composition remuneration board director corporate executive committee board director corporate executive committee annual remuneration element description c bod ceo roche group cec base pay monthly payment quarterly remuneration payment bonus annual payment year year cash block nonvoting block nonvoting equity security equity security andor share andor share pension etc perennial remuneration element stocksettle stock year appreciation right additionally ssar block nonvoting equity security exercise restrict stock year unit rsus block nonvoting equity security httpswwwrochecominvestorsreportsperformance httpswwwrochecomaboutsustainabilityenvironmentgoalsperformanceremuneration report roche lti corporate executive committee expiration period align newly enlarge corporate executive issue ssar rsus unlike committee compose ssar participant programme member rsus base exist individual corporate executive committee target value total lti corporate executive choice determine mix rsus ssar committee member base pay fouryear cliff vest measured january year vest corporate executive committee lti mix ssarsrsus fix base calculation vest period cliff vest expiration period base individual target ssar value total lti year year year corporate executive committee member base pay rsus measure january year year year remain participant ssar offer level choice empower participant rsus programme offer yearly basis engage fully total reward enable choice combination determine mix well understand critical element restrict stock unit rsus stocksettle compensation increase value stock appreciation right ssar option programme instead ssar country follow option available attractively design roche longterm incentive programme enable roche attract choice choice choice motivate retain good talent ssar ssar ssar align company longterm success rsus rsus rsus fix base salary indirect benefit employer contribution roche pension insurance contribution sti remuneration roche connect bonus tax consulting service component lti expense allowance stocksettle stock appreciation right restrict stock unit children school cost foreign tax obligation variable longterm ahvivalv employer contribution social security beneficial part base pay fix bonus variable base pay cash payment determine bonus annually award individual position base salary market datum contribution value creation business year lead global pharmaceutical company mean incentive strive footnote major swiss company outstanding result create new business footnote reflect individual ability opportunitie bonus amount link group experience performance time pay divisional core profit sale growth constant adjustment likewise link individual exchange rate operate profit capital performance account prevailing charge opac base core operating profit core market condition company overall earning share nonvoting equity security financial situation ne growth constant exchange rate product development pipeline diversity employee remuneration committee make review manager environmental goal additionally final decision individual base pay pay link achievement measurable chairman board director qualitative individual functional performance member corporate executive committee objective competitive reason roche remuneration member disclose individual performance objective board member corporate executive committee chairman httpscareersrochecomglobalendiversityandinclusion httpswwwrochecomaboutsustainabilityenvironmentgoalsperformance goal roche group httpsassetscwprochecomfxfshegoalscommunicationpdfremuneration report roche december end reporting year restrict stock unit rsus longterm january follow reporting year proportion restrict stock unit rsus remuneration committee decide bonus member corporate executive committee amount payable chairman total lti base individual board member corporate executive target value total lti corporate executive committee respect relevant reporting year committee member base pay base performance aforementione measure january year objective time remuneration committee decide form bonus rsus contain right receive nonvoting equity award ie cash payment andor block security andor share fouryear vest applicable nonvoting equity security period plus value adjustment share equivalent sum dividend pay vest period attributable number remuneration committee use discretion nonvoting equity security andor share appropriately weight criterion individual award grant bonus allocation vested recipient corporate executive committee year total employee eligible result nonvoting equity bonus roche bonus program security andor share remain block year stocksettle stock appreciation right ssar longterm rsu award allocate individually ssar proportion lti corporate corporate executive committee executive committee base remuneration committee discretion individual target value total lti corporate executive committee member rsus serve remuneration component base pay measure january year eligible roche employee ssar entitle holder benefit financially indirect benefit increase value roche nonvoting show ceo roche group equity security grant date chairman respectively member exercise date ssar grant vest corporate executive committee additionally year exercise receive indirect benefit pension fund insurance year grant date unexercised ssar contribution roche connect payment foreign lapse compensation fair tax obligation tax consulting service value ssar calculate grant annual expense allowance show date trinomial model american individual member corporate executive option detail committee receive payment family child education allowance school cost ssar corporate executive committee child allocate individually remuneration committee discretion total employee receive ssar weight fix variable longterm remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable longterm variable longterm remuneration pay member corporate executive committee range total compensation ratio variable remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar rsus relative value fix base pay lti longterm sti variable total criterion bonus ssar total lti rsus total lti individual target value minimum maximum performance criterion group objective group divisional business value development value development performance individual objective consider determined determined core profit sale growth constant exchange rate performance performance plus operating profit capital charge opac base nes grant value adjustment core operating profit core earning share dividend nonvoting equity security ne growth constant ne grant exchange rate product development pipeline diversity employee manager environmental goal split group objective na na b individual objective na na weighting criterion remuneration committee discretion decision objective na applicable assess consideration performance competitor macroeconomic development base exist individual target value total lti corporate executive committee member base pay measure january year detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration board director resolution approval form quarterly fix cash payment remuneration chairman board show remuneration member director member board director board director table decide remuneration committee board activity roche pay discretion take account market comparison employer contribution totalling chf chf social security agency remuneration form cash payment member board director annually track market datum director legally require contribution separately pay lead global pharmaceutical state chairman board director company footnote major swiss company footnote assist basic remuneration board director consultancy pwc exclude chairman remain unchanged previous year board director separately submit total aggregate exception chairman board bonus chairman board director director bonus form block share financial year general meeting dr severin schwan executive member retrospective bind approval board member board director award share nonvoting equity security maximum amount total aggregate ssar remuneration board director period ordinary general meeting loan credit grant ordinary general meeting member board director table separately previous year general meeting prospective bind advisory service genentech approval scientific resource board prof dr richard p lifton receive honoraria amount total remuneration member usd chf board director member board director receive remuneration additional compensation list member position committee membership chairmanship detidua remuneration report roche remuneration member board director chf additional remuneration additional special additional basic remuneration committee memberschair remuneration bvg cost total remuneration c franz chairman total remuneration pay chairman board director hoffmann vicechairman j duschmal p frost hauser r p lifton j mahmood march b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff member march september p bulcke march h clevers march j brown september total cost provision swiss federal occupational old age survivor invalidity pension act bvg accordance minimum requirement insurance benefit bvg half cost member board director subject compulsory insurance bear company exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board p rorate remuneration period march december prorate remuneration period january march january september respectively dditionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detidua remuneration member board director chf additional remuneration additional special additional basic remuneration committee memberschair remuneration bvg cost total remuneration c franz chairman total remuneration pay chairman board director hoffmann vicechairman j brown p bulcke h clevers j duschmal p frost hauser r p lifton b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff total cost provision swiss federal occupational old age survivor invalidity pension act bvg accordance minimum requirement insurance benefit bvg half cost member board director subject compulsory insurance borne company w ith exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay chairman year payable march board director shareholder bind vote ordinary chairman dr christoph franz receive total annual general meeting agm remuneration show remuneration committee bonus proposal chairman total remuneration contain adopt late respect total remuneration board director financial year form share block detidua remuneration report roche total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration include submission chairman total bonus employer contribution social aggregate bonus bind vote security beneficial part totalling chf annual general meeting chf exclude additional remuneration chairman board employer contribution pay social security director include bonus award chf totalling chf chf form share block year show table section total remuneration remuneration pay member pay chairman board director board director board director submit remuneration remuneration pay committee bonus proposal adopt late chairman board dr christoph franz respect financial year payable march exclude legally require employer contribution ahvivalv shareholder bind vote ordinary annual general meeting detidua total remuneration pay chairman board director chf base salary cash tax equalisation pension fund correction na bonus subject approval annual general meeting pension fund insurance annual expense allowance tax social security include employer contribution social security beneficial part total na applicable form share block year calculation number share base price date transfer march respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively dditionally employer contribution ahvivalv chf chf pay form remuneration detidua remuneration report roche retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base price date transfer march march march respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively submission board total chf exclude legally aggregate future remuneration bind require employer contribution ahvivalv shareholder vote exclude bonus period end board director propose ordinary agm ordinary agm approve board remuneration totalling prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report exclude bonus period end remuneration shareholder ordinary agm approve remuneration member board director comparison ordinary agm ordinary agm approve board ordinary agm actual remuneration remuneration totalling amount chf exclude legally chf exclude legally require require employer contribution ahvivalv employer contribution ahvivalv exclude bonus prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding statement relate party director andr hoffmann dr jrg duschmal note financial statement member founder family roche holding ltd significant shareholder closely associate belong addition december contractually bind shareholder group december respectively pool voting right end member board director person group hold share issue closely associate hold roche share share detailed information group nonvoting equity security nes american find finance report note depositary receipt adrs show roche group consolidated financial table security holding security holding share nes december december nonvoting close nonvoting close equity relative equity relative security security security security share ne number holding share ne number holding number number type numbertype number number type numbertype board director c franz hoffmann j duschmal p frost hauser ne nes r p lifton adr adrs j mahmood na na na na b poussot schwan security holding security holding corporate executive committee corporate executive committee c suessmuth dyckerhoff total adr ne adr ne na applicable share hold shareholder group pool voting right list jointly hold close relative r oche adr american depositary receipt list otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlying nesremuneration report roche remuneration corporate executive committee resolution approval remuneration member remuneration member corporate corporate executive committee executive committee decide general provision assign authority remuneration committee discretion taking decision corporate executive committee account market comparison remuneration remuneration committee board director outline previous year board remuneration decision process director separately submit total aggregate approval framework bonus corporate executive committee financial year general meeting member corporate executive retrospective bind approval committee receive remuneration work show remuneration maximum amount total aggregate ceo roche group dr severin schwan remuneration corporate executive explain detail committee period ordinary general meeting ordinary general meeting table separately previous year general meeting prospective bind approval high total remuneration pay reflect high total remuneration pay dr severin schwan member member corporate executive committee corporate executive committee include total dr severin schwan executive member pay corporate executive committee board director receive remuneration total remuneration pay member primary function ceo roche group corporate executive committee high total remuneration pay dr severin schwan member corporate executive committee chf base salary bonus subject approval total aggregate bonus corporate executive committee annual general meeting ssar rsus roche connect pension fund insurance payment incl expense allowance tax consulting service total calculation value nonvoting equity security share consideration reduction value block period year reduce market value nclude employer contribution social security beneficial part detailed calculation remuneration annual report share block year calculation number share base share price date transfer march approval agm sars number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value ssar number grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu calculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu include annual expense allowance chf payment tax consulting service chf chf family child education allowance chf chf additionally employer contribution ahvivalv chf chf pay form remuneration base pay member corporate executive committee base pay chf b anderson hippe schinecker c wilbur total detidua detidua bonus member bonus bring forward bind corporate executive committee vote annual general meeting remuneration committee board director determine corporate executive dr severin schwan members committee member bonus base corporate executive committee receive performance agree objective bonus cash payment dr severin remuneration committee use discretion schwan receive bonus form roche appropriately weight criterion share block year bonus allocation total aggregate bonus payment march bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting b anderson hippe schinecker c wilbur total detidua remuneration report roche stocksettle stock appreciation exist individual target value right ssar member total lti corporate executive committee corporate executive committee member base pay measure ssar member corporate executive january year committee allocate individually remuneration committee discretion ssar fair value ssar calculate show ssar table grant date trinomial model american entitle holder benefit financially option trinomial model effective increase value roche nonvoting equity method valuation american option security ne grant date consider possibility exercise option exercise date strike price ssar time prior maturity call american option term multiyear plan closing price compare european option roche ne grant date ssar vest allow exercise maturity date previously grant ssar year grant date vest ssar exercise number ssar strike price expiry convert ne previously grant date grant value ssar show ssar seven year grant date ssar table unexercised ssar lapse compensation number ssar calculate time issue enter value ssar proportion lti table corporate executive committee base information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar httpsassetscwprochecomfxefde trinomialmodelpdf restrict stock unit rsus rsus contain right receive nonvoting equity member corporate security andor share newly executive committee define fouryear vest period plus value proportion restrict stock unit adjustment equivalent rsus member corporate executive sum dividend pay vest period committee total lti base attributable number nonvoting equity exist individual target value total security andor share individual lti corporate executive committee member award grant vested base pay measure january recipient corporate executive committee year rsu award allocate individually year result corporate executive committee nonvoting equity security andor share remuneration committee discretion remain block year detidua detidua stocksettle stock appreciation right ssar grant value grant value number ssar chf value chf number ssar chf value chf b anderson hippe schinecker c wilbur total price chf expiry date price chf expiry date restrict stock unit rsus value grant value grant number chf value chf number chf value chf b anderson hippe schinecker c wilbur total calculation value consideration reduction value additional block period year reduce market value indirect benefit member roche nonvoting equity security nes corporate executive committee equal annual salary employer contribution social discount ne purchase plan security scheme pension plan groupwide subject hold period year employee stock purchase plan roche connect switzerland respect member corporate executive committee show indirect benefit addition member corporate executive employer contribution table committee receive annual expense allowance table member payment foreign tax obligation tax consulting service show roche connect voluntary stock purchase table plan offer employee opportunity buy detidua indirect benefit employer contribution chf payment payment annual tax tax annual tax tax pension fund expense roche consulting pension fund expense roche consulting insurance allowance connect service insurance allowance connect service b anderson hippe schinecker c wilbur total include employer contribution social security beneficial part detidua detidua remuneration report roche remuneration loan member remuneration member corporate executive committee corporate executive committee excl ceo roche group payment meet legal contractual obligation roche pay total chf total remuneration pay member chf individual member corporate executive committee corporate executive committee family calendar year member child education allowance corporate executive committee receive remuneration include bonus employer aforementione additional payment contribution social security beneficial part include total remuneration member total chf chf corporate executive committee exclude additional employer contribution pay ahvivalv totalling chf loan credit grant chf form member corporate executive remuneration committee additional remuneration maximum regular period notice member abovementione payment pay corporate executive committee month current member corporate changeofcontrol clause executive committee employment contract corporate executive committee share block year remuneration subject approval member corporate executive annual general meeting committee cash payment totalling chf respect submission corporate executive financial year chf exclude committee total aggregate bonus legally require employer contribution bind vote annual general meeting social security agency submit board director propose award propose total ordinary annual member corporate executive committee general meeting agm bind vote bonus dr severin schwan form roche retrospective approval member corporate executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv submission corporate executive compose base pay longterm incentive committee total future aggregate ssar calculate grant value remuneration bind shareholder vote consider reduction value block board director propose period applicable rsus ordinary agm approve remuneration calculate time reservation nonvoting corporate executive committee totalling equity security share consider chf exclude legally reduction value blocking period require employer contribution ahvivalv pension benefit exclude legally require exclude bonus period end employer contribution ahvivalv ordinary agm contribution expense payment foreign tax obligation tax consulting service corporate executive roche connect committee total future aggregate remuneration prospective approval member corporate executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonusesremuneration report roche reconciliation report exclude bonus period end remuneration shareholder ordinary agm prospectively approve remuneration member corporate executive comparison ordinary agm committee ordinary agm remuneration amount ordinary agm approve remuneration chf exclude legally require corporate executive committee totalling employer contribution ahvivalv chf exclude legally exclude bonus require employer contribution ahvivalv prospectively approve total remuneration member corporate executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm actual total remuneration realise total remuneration calculate end calculation end corresponding agmagm period period agm agm approve limit calculation end period agm agm yes yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus clawback accord ssar plan rule addition applicable statutory provision misconduct participant include roche longterm incentive plan include inter alia option partially reclaim distribute compensation result special circumstance clawback activity lead disciplinary action repeat willful failure perform duty employee voluntarily serve notice reasonably assign roche termination employment ssar violation law public regulation rsus unvested date commission crime termination employment lapse immediately gross negligence willful misconduct compensation employment engage conduct bring disgrace termination employment result disrepute roche andor subsidiary misconduct ssar rsus grant violation roche directive outstanding vest unvested guideline relate business conduct shall lapse immediately compensation guideline security holding annual base salary requirement accord guideline security holding fulfil year march member corporate executive case new member year committee require hold roche security start employment member corporate executive committee requirement roche security holding require hold roche security equivalent ceo roche group remain unchanged value previously respective annual base salary type security value acquire year march case new member year start employment ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary security holding associate held security show december december follow table share nonvoting equity respectively member corporate security ne ssar restrict stock executive committee person closely unit rsus share nonvoting equity security nes december december share ne close relative security holding share ne close relative security holding number number numbertype number number numbertype corporate executive committee share ne share nes schwan b anderson hippe schinecker c wilbur total remuneration report roche ssar number ssar hold december corporate executive committee schwan b anderson hippe schinecker c wilbur total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option value accord correspond annual report restrict stock unit rsus number rsus hold december corporate executive committee schwan b anderson hippe schinecker c wilbur total grant value rsu chf chf chf chf ne closing price ne closing price ne closing price ne closing price grant date grant date grant date grant date march march march march general meeting roche holding ltd basel report audit remuneration report opinion statement financial statement audit remuneration report auditor report thereon roche holding ltd company year end december audit limited opinion remuneration report information remuneration loan cover information express advance pursuant art ordinance form assurance conclusion thereon excessive remuneration list company limit share verordnung gegen connection audit remuneration bermssige vergtungen bei brsenkotierten report responsibility read aktiengesellschaften vegv section information consider mark grey line audit include information materially inconsistent respective footnote page audit financial information remuneration remuneration report report knowledge obtain audit appears materially misstate opinion information remuneration loan advance remuneration report base work perform complie swiss law art vegv conclude material misstatement information require report basis opinion fact report regard conduct audit accordance swiss law swiss standard audit sach board director responsibilitie responsibility provision remuneration report standard describe auditor board director responsible responsibility audit remuneration preparation remuneration report report section report independent accordance provision swiss law company accordance provision companys article incorporation swiss law requirement swiss internal control board director audit profession fulfil determine necessary enable preparation ethical responsibility accordance remuneration report free material requirement misstatement fraud error board director responsible designing believe audit evidence remuneration system define individual obtain sufficient appropriate provide remuneration package basis opinion auditor responsibilitie audit information remuneration report board director responsible objective obtain reasonable assurance information information comprise information remuneration information include annual report loan advance pursuant art vegv include section mark audit free material misstatement remuneration report consolidate financial fraud error issue auditor reportstatutory auditor report roche include opinion reasonable assurance btain understand internal control high level assurance guarantee relevant audit order design audit audit conduct accordance swiss procedure appropriate law sach detect material circumstance purpose misstatement exist misstatement express opinion effectiveness arise fraud error consider company internal control material individually aggregate e valuate appropriateness accounting reasonably expect influence policy reasonableness economic decision user take basis accounting estimate related remuneration report disclosure audit accordance swiss law communicate board director sach exercise professional judgement relevant committee maintain professional scepticism matter plan scope timing audit audit significant audit finding include dentify assess risk material significant deficiency internal control misstatement remuneration report identify audit fraud error design perform audit procedure responsive provide board director risk obtain audit evidence relevant committee statement sufficient appropriate provide basis comply relevant ethical requirement opinion risk detect independence communicate material misstatement result fraud relationship matter high result error reasonably think bear fraud involve collusion forgery intentional independence applicable action omission misrepresentation override take eliminate threat safeguard apply internal control kpmg ag franois rouiller paul nichols license audit expert auditor charge basel january kpmg ag grosspeteranlage ch basel kpmg ag swiss corporation subsidiary kpmg holding ag member kpmg global organization independent member firm affiliate kpmg international limited private english company limit guarantee right reserve independent practitioner limit assurance report select nonfinancial information corporate governance sustainability committee roche holding ltd basel engage corporate roche ecobalance energy use governance sustainability committee select type graph perform assurance procedure provide limited report assurance select nonfinancial information key figure table graph include greenhouse gas ghg emission page scope roche holding ltd consolidated capital good purchase good subsidiary roche group period service fuel energyrelate activity january december disclose upstream transportation waste generate annual report report operation use sell product scope subject matter criterion assurance engagement relate limited select nonfinancial information level assurance select nonfinancial include ghg emission prepare information include ghg emission corporate governance sustainability january december disclose committee roche holding ltd base report document basis preparation nonfinancial information suitable criterion follow select nonfinancial information available roche website include ghg emission publish httpsastoryblokcomfxcefae report scope limited nonfinancialreportingmetricsguidelines assurance engagement basisforpreparationpdf follow people key figure material inherent limitation aspect disclose report accuracy completeness select employee fte employee division nonfinancial information include operate divisional group odg ghg emission subject inherent limitation graph report give nature method determine share woman executive position calculate estimate datum addition table report greenhouse gas quantification subject inherent uncertainty incomplete follow safety security health scientific knowledge determine factor environmental protection key figure relate value need combine emission include ghg emission scope different gas assurance report scope result business travel read connection material aspect disclose report document basis preparation nonfinancial employee health safety table information roche group report definition procedure pricewaterhousecooper ag birchstrasse postfach ch zurich telephone wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecooper network firm separate independent legal entityindependent practitioner limit assurance report roche relate thirdparty guideline present ethical requirement professional standard select nonfinancial information applicable legal regulatory requirement corporate governance sustainability practitioner responsibility committee responsibility responsibility perform limited assurance corporate governance sustainability engagement express conclusion committee roche holding ltd responsible select nonfinancial information include preparation presentation ghg emission roche group disclose nonfinancial information include ghg report conduct engagement emission accordance document accordance international standard basis preparation nonfinancial information assurance engagement isae revise responsibility include design assurance engagement audit implementation maintenance internal review historical financial information control system relate preparation international standard assurance engagement select nonfinancial information free assurance engagement greenhouse material misstatement fraud gas statement isae issue error furthermore corporate governance international auditing assurance standard sustainability committee responsible board standard require plan selection application document perform procedure obtain limited assurance basis preparation nonfinancial information come attention adequate record keeping cause believe select nonfinancial information include ghg independence quality management emission prepare material aspect independent roche holding ltd accordance document basis accordance international code preparation nonfinancial information ethic professional accountant include international independence standard issue base risk materiality consideration international ethic standard board perform procedure obtain sufficient accountant iesba code fulfil appropriate assurance evidence ethical responsibility accordance procedure select depend assurance iesba code found fundamental practitioner judgement limited assurance principle integrity objectivity professional engagement isae revise competence care confidentiality isae substantially scope professional behaviour reasonable assurance engagement relation risk assessment procedure include pricewaterhousecoopers ag apply international understanding internal control standard quality management procedure perform response assess require firm design implement risk consequently nature timing extent operate system quality management include procedure gather sufficient appropriate policy procedure compliance evidence deliberately limited relative reasonable assurance engagement ssessment process datum assurance obtain limited assurance consolidation engagement reasonable assurance review management nonfinancial engagement reporting process people key figure perform follow assurance procedure assess aggregation process datum roche group level r eview application roche group guideline believe evidence obtain review application roche group sufficient appropriate provide basis select nonfinancial reporting guideline conclusion document basis preparation nonfinancial information conclusion base work perform ite visit management inquiry come attention cause believe visit select pharmaceutical select nonfinancial information diagnostic site costa rica spain include ghg emission roche switzerland usa selection group period january base quantitative qualitative criterion december disclose report interview personnel responsible internal prepare material respect accordance nonfinancial reporting datum collection document basis preparation site visit group level nonfinancial information determine understand application roche group nonfinancial report guideline intend user purpose report document basis preparation report prepare nonfinancial information corporate governance sustainability committee roche holding ltd solely ssessment key figure purpose report select perform test sample basis evidence nonfinancial information include ghg support select people key figure emission disclose report eg energy consumption emission air purpose give conclusion water usage discharge share woman accept assume responsibility legal executive position concern completeness accept liability connection accuracy adequacy consistency purpose report include conclusion person r eview documentation analysis relevant report show hand policy principle come person shall review relevant documentation sample entitle rely conclusion basis include roche group nonfinancial reporting policy management report structure documentationindependent practitioner limit assurance report roche permit disclosure report combination suitable criterion enable corporate governance sustainability committee demonstrate discharge governance responsibility commission independent assurance report select nonfinancial information include ghg emission assume accept responsibility liability party full extent permit law accept assume responsibility corporate governance sustainability committee roche holding ltd work report pricewaterhousecoopers ag christophe bourgoin annina binder zurich february maintenance integrity roche hold ltds website content responsibility corporate governance sustainability committee work carry assurance provider involve consideration maintenance integrity roche hold ltds website accordingly assurance provider accept responsibility change occurred specify nonfinancial information suitable criterion initially present websiteimprint cautionary statement statement earning share growth forwardlooke statement profit forecast interpret annual report contain certain forwardlooke mean roche earning earning share statement forwardlooke statement subsequent period necessarily identify word believe expect match exceed historical publish earning anticipate project intends seek earning share roche estimate future similar expression discussion thing strategy goal plan trademark legally protect intention factor cause actual result differ materially future reflect link thirdparty page provide convenience forwardlooking statement contain annual express opinion content report pricing product initiative thirdparty page expressly disclaim competitor legislative regulatory development liability thirdparty information use economic condition delay inability thereof obtain regulatory approval bring product market fluctuation currency exchange rate roche annual report publish german general financial market condition uncertaintie english discovery development marketing new product new use exist product include reporting consist actual annual report limitation negative result clinical trial finance report contain annual research project unexpected effect pipeline financial statement consolidate financial market product increase government pricing statement regard content management pressure interruption production loss report article incorporation consist inability obtain adequate protection intellectual aforementione report exception property right litigation loss key executive remuneration report employee adverse publicity news coverage print nonchlorine bleach fsccertified paperkey date annual general meeting march firstquarter sale april halfyear result july ninemonth sales october publish f hoffmannla roche ltd group communications basel switzerland tel wwwrochecom orderdownload publication internet wwwrochecompublication email materialsmanagementmmrochecom fax medium relation tel email mediarelationsrochecom investor relation tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomdoe patient need believe urgent deliver medical solution right develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochef hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom